

(19)



(11)

**EP 2 258 477 A1**

(12)

**EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 153(4) EPC

(43) Date of publication:

**08.12.2010 Bulletin 2010/49**

(21) Application number: **09705661.8**

(22) Date of filing: **28.01.2009**

(51) Int Cl.:

<b>B01J 31/02</b> <sup>(2006.01)</sup>	<b>C07C 67/347</b> <sup>(2006.01)</sup>
<b>C07C 69/738</b> <sup>(2006.01)</sup>	<b>C07C 201/12</b> <sup>(2006.01)</sup>
<b>C07C 205/56</b> <sup>(2006.01)</sup>	<b>C07B 53/00</b> <sup>(2006.01)</sup>
<b>C07B 61/00</b> <sup>(2006.01)</sup>	<b>C07D 207/325</b> <sup>(2006.01)</sup>
<b>C07D 307/54</b> <sup>(2006.01)</sup>	<b>C07D 333/24</b> <sup>(2006.01)</sup>

(86) International application number:

**PCT/JP2009/051322**

(87) International publication number:

**WO 2009/096409 (06.08.2009 Gazette 2009/32)**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL  
PT RO SE SI SK TR**

Designated Extension States:

**AL BA RS**

(30) Priority: **28.01.2008 JP 2008015906**

(71) Applicant: **Japan Science and Technology Agency  
Kawaguchi-shi  
Saitama 332-0012 (JP)**

(72) Inventors:

- **KOBAYASHI, Shu**  
Tokyo 101-0048 (JP)
- **AGOSTINHO, Magno**  
2380-608 Serra de Santo Antonio (PT)
- **SCHNEIDER, Uwe**  
Tokyo 112-0002 (JP)
- **YAMAGUCHI, Miyuki**  
Tokyo 110-0008 (JP)

(74) Representative: **Vossius & Partner**

**Siebertstrasse 4  
81675 München (DE)**

(54) **CATALYST AND REACTION PROCESS**

(57) Disclosed is a technology for enabling an efficient asymmetric Michael addition reaction which does not require a large amount of a malonic ester, while having a short reaction time. Specifically disclosed is a catalyst which is composed of MX<sup>2</sup> (wherein M is Be, Mg,

Ca, Sr, Ba or Ra and X is an arbitrary group) and a compound represented by general formula [I]. [In the formula, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> each represents a substituted cyclic group or an unsubstituted cyclic group.]

**EP 2 258 477 A1**

**Description**

[APPLICABLE FIELD IN THE INDUSTRY]

5 **[0001]** The present invention relates to a catalyst and a reaction method. The present invention relates, for example, to a technology of highly enantioselective addition reaction to an enone using a malonic ester as a nucleophile.

[BACKGROUND ART]

10 **[0002]** The reaction between a malonic ester and an enone is shown in the following documents.

Non-patent document 1: Park, S.-Y.; Morimoto, H.; Matsunaga, S.; Shibasaki, M. *Tetrahedron Lett.* 2007, 48, 2815-2818.

Non-patent document 2: Chen, C.; Zhu, S.-F.; Wu, X.-Y.; Zhou, Q.-L. *Tetrahedron: Asymmetry* 2006, 17, 2761-2767.

15 Non-patent document 3: Kumaraswamy, G.; Jena, N.; Sastry, M. N. V.; Rao, G. V.; Ankamma, K. *J. Mol. Catal. A* 2005, 230, 59-67.

Non-patent document 4: Velmathi, S.; Swarnalakshmi, S.; Narasimhan, S. *Tetrahedron: Asymmetry* 2003, 14, 113-117.

20 Non-patent document 5: Annamalai, V.; DiMauro, E. F.; Carroll, P. J.; Kozlowski, M. C. *J. Org. Chem.* 2003, 68, 1973-1981.

Non-patent document 6: Xu, Y.; Otori, K.; Ohshima, T.; Shibasaki, M. *Tetrahedron* 2002, 58, 2585-2588.

Non-patent document 7: Kumaraswamy, G.; Sastry, M. N. V.; Jena, N. *Tetrahedron Lett.* 2001, 42, 8515-8517.

Non-patent document 8: Kim, Y. S.; Matsunaga, S.; Das, J.; Sekine, A.; Ohshima, T.; Shibasaki, M. *J. Am. Chem. Soc.* 2000, 122, 6506-6507.

25 Non-patent document 9: End, N.; Macko, L.; Zehnder, M.; Pfaltz, A. *Chem. Eur. J.* 1998, 4, 818-824.

Non-patent document 10: Manickam, G.; Sundararajan, G. *Tetrahedron: Asymmetry* 1997, 8, 2271-2278.

Non-patent document 11: Sasai, H.; Arai, T.; Satow, Y.; Houk, K. N.; Shibasaki, M. *J. Am. Chem. Soc.* 1995, 117, 6194-8.

Non-patent document 12: Wang, Z.; Wang, Q.; Zhang, Y.; Bao, W. *Tetrahedron Lett.* 2005, 46, 4657-4660.

30 Non-patent document 13: Ooi, T.; Ohara, D.; Fukumoto, K.; Maruoka, K. *Org. Lett.* 2005, 7, 3195-3197.

Non-patent document 14: Dere, R. T.; Pal, R. R.; Patil, P. S.; Salunkhe, M. M. *Tetrahedron Lett.* 2003, 44, 5351-5353.

Non-patent document 15: Kim, D. Y.; Huh, S. C.; Kim, S. M. *Tetrahedron Lett.* 2001, 42, 6299-6301.

Non-patent document 16: Wang, J.; Li, H.; Zu, L.; Jiang, W.; Xie, H.; Duan, W.; Wang, W. *J. Am. Chem. Soc.* 2006, 128, 12652-12653.

35 Non-patent document 17: Knudsen, K. R.; Mitchell, C. E. T.; Ley, S. V. *Chem. Commun.* 2006, 66-68.

Non-patent document 18: Halland, N.; Aburel, P. S.; Jorgensen, K. A. *Angew. Chem., Int. Ed.* 2003, 42, 661-665.

Non-patent document 19: Yamaguchi, M.; Shiraishi, T.; Hiram, M. *J. Org. Chem.* 1996, 61, 3520-30.

Non-patent document 20: Yamaguchi, M.; Shiraishi, T.; Hiram, M. *Angew. Chem., Int. Ed.* 1993, 32, 1176-8.

40 [DISCLOSURE OF THE INVENTION]

[PROBLEMS TO BE SOLVED BY THE INVENTION]

45 **[0003]** Conventionally, an asymmetric Michael addition reaction between a malonic ester and an enone requires a large volume of a malonic ester so as to gain a high yield. Yet, a reaction time thereof is long. For this, the prior art is poor in efficiency.

**[0004]** Thus, a task that the present invention is to solve, that is, an object of the present invention is to provide, for example, a technology for enabling an efficient asymmetric Michael addition reaction that does not require a large amount of a malonic ester, while having a short reaction time.


50

[MEANS FOR SOLVING THE PROBLEM]

**[0005]** The foregoing problems are solved by a catalyst configured using  $\text{MX}_2$  (wherein M is Be, Mg, Ca, Sr, Ba or Ra and X is an arbitrary group) and a compound represented by the following general formula [I].

55

General formula [I]



[R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, and R<sup>10</sup> each represents a substituted cyclic group or an unsubstituted cyclic group. There are two cases for R<sup>9</sup> and R<sup>10</sup>, i.e. the case that they form a ring and the case that they do not form a ring.]

15 **[0006]** And, the foregoing problems are solved by the above-mentioned catalyst that is characterized in that the foregoing X is an alkoxide group. Among others, the foregoing problems are solved by the above-mentioned catalyst that is characterized in that the foregoing MX<sub>2</sub> is M(OR<sup>5</sup>)<sub>2</sub> (M is Mg, Ca, Sr or Ba. R<sup>5</sup> is an alkyl group). More preferably, the foregoing problems are solved by the above-mentioned catalyst that is characterized in that the foregoing MX<sub>2</sub> is M(OR<sup>5</sup>)<sub>2</sub> (M is Ca, Sr or Ba. R<sup>5</sup> is an alkyl group having a carbon number of 1 to 10). In particular, the foregoing problems are solved by the above-mentioned catalyst that is characterized in that the foregoing MX<sub>2</sub> is Sr(OR<sup>5</sup>)<sub>2</sub> (R<sup>5</sup> is an alkyl group having a carbon number of 1 to 10).

20 **[0007]** Further, the foregoing problems are solved by the above-mentioned catalyst that is characterized in that the foregoing X is an amide group. In particular, the foregoing problems are solved by the above-mentioned catalyst that is characterized in that the foregoing X is hexamethyldisilazide (HMDS).


25 **[0008]** Further, the foregoing problems are solved by the above-mentioned catalyst that is characterized in that the foregoing cyclic group of the foregoing general formula [I] is an aromatic group.

**[0009]** Further, the foregoing problems are solved by the above-mentioned catalyst that is characterized in that the compound represented by the foregoing general formula [I] and M of the foregoing compound MX<sub>2</sub> are coordinate-bonded to each other.


30 **[0010]** The above-mentioned catalyst is a catalyst that is used for a reaction between a compound represented by the following general formula [II] and a compound represented by the following general formula [III].

**[0011]**

General formula [II]



General formula [III]



[0012] Each of the foregoing  $R^1$ ,  $R^2$ ,  $R^3$ , and  $R^4$  is an arbitrary substituent. Preferably, it is an H group or a hydrocarbon group.

[0013] Each of the foregoing  $W^1$ ,  $W^2$ , and  $W^3$  is an electron-withdrawing group. Preferably, it is an ester group or a carbonyl group.

5 [0014] The compound represented by the foregoing general formula [II] is, particularly, a dicarboxylate ester. Among others, it is a malonic ester.

[0015] The compound represented by the foregoing general formula [III] is, particularly, an enone.

10 [0016] Further, the foregoing problems are solved by a reaction method that is characterized in reacting the compound represented by the foregoing general formula [II] with the compound represented by the foregoing general formula [III] in the presence of the foregoing catalyst.


[0017] A molecular sieve is preferably added to a solution of the foregoing reaction. Further, an aromatic hydrocarbon solvent is preferably used as a solvent of the foregoing reaction.

[0018] And, a compound represented by the following general formula [IV] is obtained with the above-mentioned reaction.

15 [0019]

General formula [IV]

20



25

30 [AN ADVANTAGEOUS EFFECT OF THE INVENTION]

[0020] A large amount of the compound of the foregoing general formula [II] such as a malonic ester is not required in the asymmetric Michael addition reaction between the compound of the foregoing general formula [II] (for example, a dicarboxylate ester such as a malonic ester) and the compound of the foregoing general formula [III] (for example, an enone).

35

[0021] And, the reaction time was shortened.

[0022] That is, the compound of the foregoing general formula [IV] was efficiently obtained.

[BEST MODE FOR CARRYING OUT THE INVENTION]

40

[0023] The present invention relates to a catalyst. In particular, the present invention relates a catalyst that is used for the reaction between the compound represented by the foregoing general formula [II] and the compound represented by the foregoing general formula [III]. Each of the foregoing  $R^1$ ,  $R^2$ ,  $R^3$ , and  $R^4$  of the foregoing general formula [II] and general formula [III] is an arbitrary substituent. In particular, it is an H group or a hydrocarbon group. Each of the foregoing  $W^1$ ,  $W^2$ , and  $W^3$  of the foregoing general formula [II] and general formula [III] is an electron-withdrawing group. For example, it is an electron-withdrawing group such as an ester group, a carboxyl group, a carbonyl group, a nitrile group, a nitro group, and a hydroxyl group. The particularly preferable electron-withdrawing group is an ester group and a carbonyl group. The preferable compound of the foregoing general formula [II] is a dicarboxylate ester. Among others, it is a malonic ester. In particular, it is a malonic ester represented by  $R^aOOCCH_2COOR^b$  (each of  $R^a$  and  $R^b$  is a hydrocarbon group. In particular, it is a hydrocarbon group having a carbon number of 1 to 10. For example, it is an alkyl group having a carbon number of 1 to 6.) The preferable compound of the foregoing general formula [III] is an enone.

45

50

[0024] The catalyst of the present invention is configured using a compound A and a compound B. The compound A is a compound represented by  $MX_2$  (M is a member selected from a group of alkaline earth metals. X is an arbitrary group.) The compound B is a compound represented by the foregoing general formula [I]. The alkaline earth metal is Be, Mg, Ca, Sr, Ba, or Ra. The preferable alkaline earth metal is Mg, Ca, Sr, or Ba. The particularly preferable alkaline earth metal is Ca, Sr, or Ba. Among others, it is Sr. Any group is acceptable as far as the group X bonded with the alkaline earth metal is concerned. The preferable group, out of the group X, is an alkoxide group. For example, it is an alkoxide group having a carbon number of 1 to 10. More preferably, it is an alkoxide group having a carbon number of

55

1 to 6. For example, it is a propoxide group such as i-propoxide group, or a butoxide group such as a tert-butoxide group. An amide group is also a preferable group instead of the foregoing alkoxide group. For example, hexamethyldisilazide (HMDS) is a particularly preferable group similarly to the propoxide group. That is, isopropanol is generated within a reaction system when strontium isopropoxide is used as the foregoing  $\text{MX}_2$ . On the other hand, hexamethyldisilazane (base) is generated within a reaction system when strontium hexamethyldisilazide is used as the foregoing  $\text{MX}_2$ . Thus, the reaction progresses without the base added. Therefore, the above reaction is applicable to other reaction requiring the base. Further, using hexamethyldisilazide allowed the reaction to progress at a high yield and highly enantioselectively, similarly to the case of using isopropoxide. Each of  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ , and  $\text{R}^{10}$  of the foregoing general formula [I] is a cyclic group. There are two cases for this cyclic group, i.e. the case of having a substituent and the case of not having a substituent. The preferable cyclic group is an aromatic group. For example, it is a phenyl group. Or it is a phenyl group having a substituent. Additionally, with regard to  $\text{R}^9$  and  $\text{R}^{10}$ , there is the case that a ring is formed by  $\text{R}^9$  and  $\text{R}^{10}$ . Needless to say, there is case that no ring is formed. And, the catalyst of the present invention is configured using the foregoing compound A and the foregoing compound B. For example, mixing the foregoing compound A and the foregoing compound B allows the catalyst of the present invention to be configured. For example, the catalyst (the catalysts of the present invention) assuming a structure in which the alkaline earth metal has been coordinate-bonded to an asymmetric ligand represented by the foregoing general formula [I] is configured. A preferable mixture ratio of the foregoing compound A and the foregoing compound B is A:B=1:1 to 2 (mole ratio).

**[0025]** The present invention also relates to a reaction method. In particular, the present invention relates a reaction method of obtaining the compound represented by the foregoing general formula [IV]. That is, the method of the present invention is a method of reacting the compound represented by the foregoing general formula [II] with the compound represented by the foregoing general formula [III] in the presence of the foregoing catalyst of the present invention. An amount of the catalyst is 0.01 to 20 parts by mass to 100 parts by mass of a substrate. In particular, it is 0.5 to 10 parts by mass. The reaction is conducted at temperature of 0 °C to room temperature. Molecular sieve is preferably added to a solution of this reaction. Further, an aromatic hydrocarbon solvent such as toluene, xylene, and benzene, is preferably used as a solvent.

**[0026]** Hereinafter, the present invention will be explained more specifically.

**[0027]** As the compound A represented by  $\text{MX}_2$ , calcium isopropoxide ( $\text{Ca}(\text{O-i-Pr})_2$ ), strontium isopropoxide ( $\text{Sr}(\text{O-i-Pr})_2$ ), barium butoxide ( $\text{Ba}(\text{O-t-Bu})_2$ ), magnesium butoxide ( $\text{Mg}(\text{O-t-Bu})_2$ ) were used.

**[0028]**  $\text{Ca}(\text{O-i-Pr})_2$  was procured from Sigma-Aldrich Company.  $\text{Sr}(\text{O-i-Pr})_2$  and  $\text{Ba}(\text{O-t-Bu})_2$  were procured from JAPAN PURE CHEMICAL CO., LTD.  $\text{Mg}(\text{O-t-Bu})_2$  was procured from Alfa Aesar Company.

**[0029]** An asymmetric ligand III represented by the general formula [I] in accordance with the present invention was synthesized with the method described in the document (Evans, D. A.; Nelson, S. G. J. Am. Chem. Soc. 1997, 119, 6452 to 6453). An asymmetric ligand I, being a comparative example, was synthesized with the method described in the document (Lowenthal, R. E.; Abiko, A.; Masamune, S. Tetrahedron Lett. 1990, 31, 6005-8). An asymmetric ligand II, being a comparative example, was synthesized with the method described in the document (Hilgraf, R.; Pfaltz, A. Adv. Synth. Catal. 2005, 347, 61- 77).

**[0030]** A malonic ester 1a (where R is Me), a malonic ester 1b (where R is Et), a malonic ester 1c (where R is n-Pr), a malonic ester 1e (where R is n-Bu), and a malonic ester 1f (where R is Bn (benzyl group)) shown in Table 2 were procured from TOKYO CHEMICAL INDUSTRY CO., LTD. (TCI). A malonic ester 1d (where R is i-Pr) was procured from Wako Pure Chemical industries, LTD.

**[0031]**  $\alpha,\beta$ -unsaturated carbonyl compounds 2a, 2b, 2c, 2d, 2e, 2f, 2g, 2h, 2i, 2j, 2k, 2l, 2m, 2n, 2o, 2p, 2q, 2t, and 2u shown in Table 3 were procured from TCI, Sigma-Aldrich Company, Alfa Aesar Company, Acros Company, and Wako Pure Chemical industries, LTD. An  $\alpha,\beta$ -unsaturated carbonyl compound 2r shown in Table 3 was synthesized with the method described in the document (Bhagat, S.; Sharma, R.; Sawant, D. M.; Sharma, L.; Chakraborti, A. K. J. Mol. Catal. A: Chem. 2006, 244, 20-24). An  $\alpha,\beta$ -unsaturated carbonyl compound 2s shown in Table 3 was synthesized with the method described in the document (Evans, D. A.; Borg, G.; Scheidt, K. A. Angew. Chem., Int. Ed. 2002, 41, 3188-3191). Additionally, the above-mentioned  $\alpha,\beta$ -unsaturated carbonyl compounds 2b to 2u are equivalent to entries 1 to 20 of Table 3, respectively.


**[0032]** Molecular sieves (powder) were procured from Aldrich Company, and activated (200 °C,

<1mmHg, 16 hours) for use.

**[0033]** Toluene was procured from Wako Pure Chemical industries, LTD. And, this toluene (anhydride solvent) was distilled in the presence of benzophenone and sodium.

**[0034]**

## [Asymmetric ligand III]




(1R,2R)-1,2-Diphenylethane-1,2-bis(2,5-dimethylphenyl)sulfonamide:

$^1\text{H}$  NMR (600.2 MHz, THF- $\text{D}_8$ , TMS):  $\delta$  = 7.37 (s, 2H; Ar), 7.06-6.81 (m, 12H; Ar, NH), 6.72-6.67 (m, 4H; Ar), 4.43 (m, 2H, CH), 2.40 (s, 6H, CH<sub>3</sub>), 2.14 (s, 6H, CH<sub>3</sub>);  $^{13}\text{C}\{^1\text{H}\}$  NMR (150.9 MHz, THF- $\text{D}_8$ , TMS):  $\delta$  = 140.0, 138.2, 136.1, 134.6, 133.2, 132.7, 130.3, 128.7, 128.2, 127.9, 63.3, 20.6, 19.7;  $[\alpha]_{\text{D}}^{21} = +40.27$  (c = 1.0 in  $\text{CHCl}_3$ ), for the SS enantiomer of III Evans reported  $[\alpha]_{\text{D}} = -42$  (c = 0.96 in  $\text{CHCl}_3$ ).

[0035]

## [Complex A]




30 The complex A was prepared by stirring  $\text{Sr}(\text{O}-i\text{-Pr})_2$  (0.15 mmol) in one equivalent of the asymmetric ligand III, and deuterated THF (0.75 mL) for two hours.

[0036]  $^1\text{H}$  NMR (600.2 MHz, THF- $\text{D}_8$ , TMS):  $\delta$  = 7.40-6.60 (br m, 16H; Ar), 4.40 (br m, 2H; CH), 3.86-3.79 (m, 2H; CH free *i*-PrOH), 3.43 (d,  $3J_{\text{HH}} = 3.6$  Hz, 2H; OH free *i*-PrOH), 2.53 (br s, 6H; CH<sub>3</sub>), 1.44 (br s, 6H; CH<sub>3</sub>), 1.06 (d,  $J_{\text{HH}} = 6.1$  Hz, 12H; CH<sub>3</sub> free *i*-PrOH);  $^{13}\text{C}\{^1\text{H}\}$  NMR (150.9 MHz, THF- $\text{D}_8$ , TMS):  $\delta$  = 145.6, 144.8, 134.9, 134.2, 131.6, 130.8, 129.7, 127.7, 125.9, 69.4, 63.6 (free *i*-PrOH), 25.9 (free *i*-PrOH), 21.1, 20.3.

[0037]

## [Complex B]



The complex B was prepared by adding one equivalent of dimethyl malonate (1a, 17  $\mu\text{L}$ ) to THF(H=D) containing the complex A.


[0038] And, NMR thereof was observed in a solution state.

$^{13}\text{C}\{^1\text{H}\}$  NMR (150.9 MHz, THF- $\text{D}_8$ , TMS) selected data:  $\delta$  = 174.6 (COO, coordinated malonate), 68.8 (NCH, ligand), 64.6 (CH<sub>2</sub>, malonate), 63.6 (free *i*-PrOH), 49.7 (OCH<sub>3</sub>, malonate), 25.9 (free *i*-PrOH), 20.6 (CH<sub>3</sub>, ligand), 19.8 (CH<sub>3</sub>, ligand).

[A method of preparing a crude material]

**[0039]**

5



10

**[0040]** 3-(5-Methylfuran-2-yl)-1-phenylprop-2-en-1-one


It was prepared with the method described in the document (Bhagat, S.; Sharma, R.; Sawant, D. M.; Sharma, L.; Chakraborti, A. K. J. Mol. Catal. A: Chem. 2006, 244, 20-24).

(Yield 63%), Yellow solid, Mp 57-61 °C : IR[cm<sup>-1</sup>] (KBr): 1580, 1520, 1367, 1016; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ= 8.05-8.01 (m, 2H), 7.58-7.46 (m, 4H), 7.38 (d, J<sub>HH</sub> = 15.2 Hz, 1H), 6.62 (d, J<sub>HH</sub> = 3.4 Hz, 1H), 6.13 (d, J<sub>HH</sub> = 3.4 Hz, 1H), 2.39 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ= 189.8, 155.9, 150.3, 138.4, 132.5, 130.8, 128.5, 128.4, 118.3, 117.5, 109.4, 109.3, 14.0; ESI-HRMS (m/z) calcd. for C<sub>14</sub>H<sub>13</sub>O<sub>2</sub> ((M+H)<sup>+</sup>): 213.0916, found: 213.0924, calcd. for C<sub>14</sub>H<sub>12</sub>O<sub>2</sub>Na ((M+Na)<sup>+</sup>): 235.0735, found: 235.0732.

20

**[0041]**

25



30

3-Phenyl-1-(1H-pyrrol-1-yl)prop-2-en-1-one

It was prepared with the method described in the document (Evans, D. A.; Borg, G.; Scheidt, K. A. Angew. Chem., Int. Ed. 2002, 41, 3188-3191).

White solid, Mp 101-105 °C: IR [cm<sup>-1</sup>] (KBr): 1689, 1624, 1468, 1352; <sup>1</sup>H NMR (495.1 MHz, CDCl<sub>3</sub>, TMS): δ= 7.99 (d, J<sub>HH</sub> = 15.5 Hz, 1H), 7.64-7.60 (m, 2H), 7.48-7.41 (m, 5H), 7.14 (d, J<sub>HH</sub> = 15.5 Hz, 1H), 6.36 (appearance of t, J<sub>HH</sub> = 2.4 Hz, 2H); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 162.9, 147.5, 134.2, 130.9, 129.0, 128.4, 119.3, 115.7, 113.4.

35

[A general manipulation of the catalytic asymmetric Michael reaction]

40

**[0042]** A flask with a capacity of 30 mL was heated and dried. A toluene (1.0 mL) suspension of Sr(O-i-Pr)<sub>2</sub> (0.015 mmol), the foregoing ligand III (0.018 mmol), and molecular sieves MS 4A (100 mg) were poured into this flask. And it was stirred for two hours at room temperature.

**[0043]** Thereafter, a toluene (1.0 mL) solution of diethyl malonate (0.36 mmol) and a toluene (1.0 mL) solution of chalcone (0.30 mmol) were sequentially added.

**[0044]** After confirming the finishing of the reaction by use of TLC, a saturated ammonium chloride aqueous solution NH<sub>4</sub>Cl (10 mL) was added. And an organic phase was separated by adding methylene chloride (CH<sub>2</sub>Cl<sub>2</sub>, 10 mL), and was extracted from a water phase with methylene chloride CH<sub>2</sub>Cl<sub>2</sub> (15 mL x 3).

**[0045]** The organic phase was collected, and dried over anhydrous sodium sulfate.

**[0046]** After filtering and concentration under reduced pressure, the crude product was refined with a preparative thin-layer chromatography (hexane/ethyl acetate=4/1). With this, the target compound was obtained.


**[0047]** Enantioselectivity was determined by an HPLC analysis of the target compound.

**[0048]** Additionally, the above-mentioned reaction formula is shown in the following Table 1 to Table 3.

**[0049]**

55

EP 2 258 477 A1




10 Dimethyl

2-(3-oxo-1,3-diphenylpropyl)malonate (table 2, entry 1)

It was synthesized in accordance with the above-mentioned manipulation.

Yield 65%, White solid, Mp 77-80 °C:IR [cm<sup>-1</sup>] (KBr): 1730, 1680, 1239, 1157:<sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS):δ= 7.91-7.88 (m, 2H; Ar), 7.55-7.50 (m, 1H; Ar), 7.44-7.39 (m, 2H; Ar), 7.27-7.22 (m, 4H; Ar), 7.20-7.15 (m, 1H; Ar), 4.22-4.16 (m, 1H; CH), 3.88-3.85 (m, 1H; CH), 3.72 (s, 3H, CH<sub>3</sub>), 3.56-3.46 (m, 5H; CH<sub>2</sub>, CH<sub>3</sub>), <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ= 197.5, 168.7, 168.1, 140.4, 136.8, 133.1, 128.5, 128.5, 128.1 (from intensity corresponds to 2 peaks), 127.2, 57.3, 52.6, 42.3, 40.7:HPLC (Chiralpak AS-H, hexane/*i*-propanol = 19/1, flow rate 0.5mL/min, λ= 254 nm):t<sub>major</sub> = 38.7 min, t<sub>minor</sub> = 46.3 min, ee = 94%:[α]<sub>D</sub><sup>21</sup> = +27.37 (c = 2.0 in CHCl<sub>3</sub>), literature value reported by Shibasaki<sup>7</sup> for the S enantiomer [α]<sub>D</sub><sup>41</sup> = +25.64 (c = 2.0 in CHCl<sub>3</sub>, 77% ee); ESI-HRMS (m/z) calcd. for C<sub>20</sub>H<sub>20</sub>O<sub>5</sub>Na ((M+Na)<sup>+</sup>): 363.1208, found: 363.1282.

20 [0050]



30 Diethyl


2-(3-oxo-1,3-diphenylpropyl)malonate (table 2, entry 2)

It was synthesized in accordance with the above-mentioned manipulation.

Yield 97%, White solid, Mp 62-66 °C:IR [cm<sup>-1</sup>] (KBr): 1731, 1685, 1288, 1241:<sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS):δ= 7.90-7.86 (m, 2H; Ar), 7.52-7.49 (m, 1H; Ar), 7.42-7.38 (m, 2H; Ar), 7.28-7.21 (m, 4H; Ar), 7.17-7.13 (m, 1H; Ar), 4.24-4.14 (m, 3 H; CH, OCH<sub>2</sub>), 3.94 (q, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; OCH<sub>2</sub>), 3.83 (d, <sup>3</sup>J<sub>HH</sub> = 9.6 Hz, 1H; CH), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.54, δ<sub>B</sub> = 3.46, <sup>2</sup>J<sub>AB</sub> = 16.6, <sup>3</sup>J<sub>AM</sub> = 4.4, <sup>3</sup>J<sub>BM</sub> = 9.1 Hz, 2H; CH<sub>2</sub>), 1.23 (t, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 3H; CH<sub>3</sub>), 1.00 (t, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS):δ= 197.5, 168.4, 167.1, 140.5, 136.8, 133.0, 128.5, 128.4, 128.2, 128.1, 127.1, 61.6, 61.3, 57.6, 42.6, 40.8, 14.0, 13.8:HPLC (Chiralpak AS-H, hexane/*i*-propanol = 19/1, flow rate 0.5 mL/min, λ= 254 nm):t<sub>major</sub> = 28.1 min, t<sub>minor</sub> = 31.8 min, ee = 97%

[α]<sub>D</sub><sup>22</sup> = +19.39 (c = 1.0 in CHCl<sub>3</sub>), [α]<sub>D</sub><sup>19</sup> = +6.35 (c = 2.5 in benzene), literature value reported by Koga<sup>9</sup> for the S enantiomer [α]<sub>D</sub><sup>25</sup> = +5.4 (c = 2.61 in benzene, 82% ee):ESI-HRMS (m/z) calcd. for C<sub>22</sub>H<sub>24</sub>O<sub>5</sub>Na ((M+Na)<sup>+</sup>): 391.1521, found: 391.1502.

45 [0051]






## Dipropyl

2-(3-oxo-1,3-diphenylpropyl)malonate (table 2, entry 3)

It was synthesized in accordance with the above-mentioned manipulation.

Yield 92%, White solid, Mp 55-58 °C; IR [cm<sup>-1</sup>] (KBr): 1725, 1686, 1293, 1241, 1168; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.89-7.87 (m, 2H; Ar), 7.52-7.49 (m, 1H; Ar), 7.42-7.38 (m, 2H; Ar), 7.28-7.21 (m, 4H; Ar), 7.17-7.13 (m, 1H; Ar), 4.19 (t d, <sup>3</sup>J<sub>HH</sub> = 4.5, <sup>3</sup>J<sub>HH</sub> = 9.4 Hz, 1H; CH), 4.14-4.05 (m, 2H; OCH<sub>2</sub>), 3.87-3.83 (m, 3H; CH, OCH<sub>2</sub>), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.54, δ<sub>B</sub> = 3.47, <sup>2</sup>J<sub>AB</sub> = 16.7, <sup>3</sup>J<sub>AM</sub> = 4.6, <sup>3</sup>J<sub>BM</sub> = 9.1 Hz, 2H; CH<sub>2</sub>), 1.63 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.47-1.37 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.90 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>), 0.77 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 197.6, 168.5, 167.9, 140.6, 136.9, 133.0, 128.5, 128.4, 128.2, 128.1, 127.1, 67.2, 66.9, 57.6, 42.6, 40.8, 21.8, 21.6, 10.3, 10.2; HPLC (Chiralpak AS-H, hexane/*i*-propanol = 100/1, flow rate 0.5 mL/min, λ = 254 nm): t<sub>major</sub> = 47.2 min, t<sub>minor</sub> = 52.0 min, ee = 99%; [α]<sub>D</sub><sup>21</sup> = +24.29 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>24</sub>H<sub>28</sub>O<sub>5</sub>Na ((M+Na)<sup>+</sup>): 419.1834, found: 419.1865.


**[0052]**

## Diisopropyl

2-(3-oxo-1,3-diphenylpropyl)malonate (table 2, entry 7)

It was synthesized in accordance with the above-mentioned manipulation.

Yield 83%, White solid, Mp 69-71 °C; IR [cm<sup>-1</sup>] (KBr): 1725, 1685, 1283, 1239, 1106; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.90-7.86 (m, 2H; Ar), 7.52-7.48 (m, 1H; Ar), 7.40 (br t, <sup>3</sup>J<sub>HH</sub> = 7.7 Hz, 2H; Ar), 7.27-7.19 (m, 4H; Ar), 7.16-7.12 (m, 1H; Ar), 5.07 (sept, <sup>3</sup>J<sub>HH</sub> = 6.2 Hz, 1H; CH), 4.79 (sept, <sup>3</sup>J<sub>HH</sub> = 6.3 Hz, 1H; CH), 4.16 (t d, <sup>3</sup>J<sub>HH</sub> = 9.7, <sup>3</sup>J<sub>HH</sub> = 4.1 Hz, 1H; CH), 3.78 (d, <sup>3</sup>J<sub>HH</sub> = 9.7 Hz, 1H; CH), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.53, δ<sub>B</sub> = 3.43, <sup>2</sup>J<sub>AB</sub> = 16.5, <sup>3</sup>J<sub>AM</sub> = 4.1, <sup>3</sup>J<sub>BM</sub> = 9.7 Hz, 2H; CH<sub>2</sub>), 1.23 (d, <sup>3</sup>J<sub>HH</sub> = 6.3 Hz, 6H; CH<sub>3</sub>), 1.04 (d, <sup>3</sup>J<sub>HH</sub> = 6.2 Hz, 3H; CH<sub>3</sub>), 0.96 (d, <sup>3</sup>J<sub>HH</sub> = 6.2 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 197.6, 167.9, 167.2, 140.5, 136.9, 133.0, 128.5, 128.4, 128.3, 128.1, 127.0, 69.2, 68.8, 57.9, 42.9, 40.7, 21.7, 21.5, 21.3, 21.3; HPLC (Chiracel OD-H, hexane/*i*-propanol = 9/1, flow rate 0.5 mL/min, λ = 254 nm): t<sub>major</sub> = 12.4 min, t<sub>minor</sub> = 13.7 min, ee = 89%; [α]<sub>D</sub><sup>22</sup> = +21.27 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>24</sub>H<sub>28</sub>O<sub>5</sub>Na ((M+Na)<sup>+</sup>): 419.1834, found: 419.1898.

**[0053]**

## Dibutyl

2-(3-oxo-1,3-diphenylpropyl)malonate (table 2, entry 8)


It was synthesized in accordance with the above-mentioned manipulation.

Yield 85%, Colorless liquid; IR [cm<sup>-1</sup>] (neat): 1733, 1687, 1254, 1223, 1158; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.90-7.87 (m, 2H; Ar), 7.52-7.48 (m, 1H; Ar), 7.41-7.38 (m, 2H; Ar), 7.28-7.20 (m, 4H; Ar), 7.17-7.13 (m, 1H; Ar), 4.21-4.09 (m, 3H; CH, OCH<sub>2</sub>), 3.92-3.84 (m, 3H; CH, OCH<sub>2</sub>), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.54, δ<sub>B</sub> = 3.46, <sup>2</sup>J<sub>AB</sub> = 16.7, <sup>3</sup>J<sub>AM</sub> = 4.5, <sup>3</sup>J<sub>BM</sub> = 9.3 Hz, 2H; CH<sub>2</sub>), 1.61-1.55 (m, 2H; CH<sub>2</sub>), 1.41-1.30 (m, 4H; CH<sub>2</sub>), 1.22-1.15 (m, 2H; CH<sub>2</sub>), 0.89 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>), 0.82 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 197.5, 168.5, 167.8, 140.6, 136.9, 133.0, 128.5, 128.4, 128.2, 128.1, 127.1, 65.5, 65.2, 57.6, 42.6, 40.8, 30.5, 30.3, 19.0, 18.9,

EP 2 258 477 A1

13.6, 13.6; HPLC (Chiralpak AS-H, hexane/*i*-propanol = 100/1, flow rate 1.0 mL/min,  $\lambda$  = 254 nm):  $t_{\text{major}}$  = 28.2 min,  $t_{\text{minor}}$  = 29.9 min, ee = 96%;  $[\alpha]_{\text{D}}^{22}$  = +19.65 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>26</sub>H<sub>32</sub>O<sub>5</sub>Na ((M+Na)<sup>+</sup>): 447.2147, found: 447.2145, calcd. for C<sub>26</sub>H<sub>33</sub>O<sub>5</sub> ((M+H)<sup>+</sup>): 425.2328, found: 425.2316.

[0054]




15 Dibenzyl

2-(3-oxo-1,3-diphenylpropyl)malonate (table 2, entry 9)

It was synthesized in accordance with the above-mentioned manipulation.

Yield 85%, White solid, Mp 89-92 °C; IR [cm<sup>-1</sup>] (KBr): 1735, 1682, 1230, 1154; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.82-7.77 (m, 2H; Ar), 7.52-7.47 (m, 1H; Ar), 7.39-7.35 (m, 2H; Ar), 7.29-7.13 (m, 13H; Ar), 7.07-7.04 (m, 2H; Ar), 5.18-5.09 (m, 2H; OCH<sub>2</sub>), 4.90 (s, 2H; OCH<sub>2</sub>), 4.25-4.19 (m, 1H; CH), 3.97-3.92 (m, 1H; CH), 3.47-3.42 (m, 2H; CH<sub>2</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 197.3, 168.0, 167.5, 140.3, 136.7, 135.1, 135.0, 133.0, 128.5, 128.4, 128.3, 128.1, 128.0, 127.2, 67.3, 67.1, 57.5, 42.2, 40.7; HPLC (Chiralpak AS-H, hexane/*i*-propanol = 19/1, flow rate 0.5 mL/min,  $\lambda$  = 254 nm):  $t_{\text{major}}$  = 56.3 min,  $t_{\text{minor}}$  = 63.7 min, ee = 84%;  $[\alpha]_{\text{D}}^{21}$  = +17.55 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>32</sub>H<sub>28</sub>O<sub>5</sub>Na ((M+Na)<sup>+</sup>): 515.1834, found: 515.1847.

[0055]



Dipropyl


2-(1-(2-chlorophenyl)-3-oxo-3-phenylpropyl)malonate (table 3, entry 1)

It was synthesized in accordance with the above-mentioned manipulation.

Yield 76%, Colorless liquid; IR [cm<sup>-1</sup>] (neat): 1730, 1687, 1266, 1227, 1160, 738; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 7.94-7.90 (m, 2H; Ar), 7.54-7.49 (m, 1H; Ar), 7.41 (appearance of br t, <sup>3</sup>J<sub>HH</sub> = 7.8 Hz, 2H; Ar), 7.34-7.30 (m, 2H; Ar), 7.16-7.09 (m, 2H; Ar), 4.66 (t d, <sup>3</sup>J<sub>HH</sub> = 8.8, <sup>3</sup>J<sub>HH</sub> = 4.3 Hz, 1H; CH), 4.13-4.00 (m, 3H; CH, OCH<sub>2</sub>), 3.94 (t, <sup>3</sup>J<sub>HH</sub> = 6.7 Hz, 2H; OCH<sub>2</sub>), ABM spin system (A = B = M = H,  $\delta_A$  = 3.71,  $\delta_B$  = 3.62, <sup>2</sup>J<sub>AB</sub> = 17.2, <sup>3</sup>J<sub>AM</sub> = 9.1, <sup>3</sup>J<sub>BM</sub> = 4.3 Hz, 2H; CH<sub>2</sub>), 1.63-1.45 (m, 4H; CH<sub>2</sub>CH<sub>3</sub>), 0.86 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>), 0.83 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS):  $\delta$  = 197.5, 168.4, 167.9, 137.9, 136.8, 134.1, 133.1, 130.1, 129.4, 128.5, 128.2, 128.1, 126.8, 67.1, 67.1, 55.2, 40.3, 37.4, 21.8, 21.7, 10.2, 10.2; HPLC (Chiracel OJ-H, hexane/*i*-propanol = 9/1, flow rate 0.5 mL/min,  $\lambda$  = 254 nm):  $t_{\text{major}}$  = 20.5 min,  $t_{\text{minor}}$  = 26.6 min, ee = 92%;  $[\alpha]_{\text{D}}^{22}$  = +41.20 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>24</sub>H<sub>27</sub>ClO<sub>5</sub>Na ((M+Na)<sup>+</sup>): 453.1445, found: 453.1437.

[0056]

EP 2 258 477 A1




Dipropyl

2-(1-(4-chlorophenyl)-3-oxo-3-phenylpropyl)malonate (table 3, entry 2)

It was synthesized in accordance with the above-mentioned manipulation.

15 Yield 93%, White solid, Mp 91-94 °C; IR [cm<sup>-1</sup>] (KBr): 1727, 1686, 1239; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.88 (br d, <sup>3</sup>J<sub>HH</sub> = 7.2 Hz, 2H; Ar), 7.52 (appearance of br t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 1H; Ar), 7.41 (t, <sup>3</sup>J<sub>HH</sub> = 7.8 Hz, 2H; Ar), 7.23-7.19 (m, 4H; Ar), 4.19-4.05 (m, 3H; CH, OCH<sub>2</sub>), 3.88 (t, <sup>3</sup>J<sub>HH</sub> = 6.6 Hz, 2H; OCH<sub>2</sub>), 3.82 (d, <sup>3</sup>J<sub>HH</sub> = 9.5 Hz, 1H; CH), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.53, δ<sub>B</sub> = 3.45, <sup>2</sup>J<sub>AB</sub> = 17.0, <sup>3</sup>J<sub>AM</sub> = 4.2, <sup>3</sup>J<sub>BM</sub> = 9.5 Hz, 2H; CH<sub>2</sub>), 1.64 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.2 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.50-1.41 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.90 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>), 0.79 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 197.3, 168.2, 167.7, 139.1, 136.7, 133.2, 132.9, 129.7, 128.6, 128.5, 128.0, 67.3, 67.1, 57.4, 42.4, 40.2, 21.8, 21.7, 10.3, 10.2; HPLC (Chiracel OJ-H, hexane/*i*-propanol = 19/1, flow rate 0.3 mL/min, λ = 254 nm): t<sub>major</sub> = 47.8 min, t<sub>minor</sub> = 54.8 min, ee = 97%; [α]<sub>D</sub><sup>22</sup> = +24.09 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>24</sub>H<sub>27</sub>ClO<sub>5</sub>Na ((M+Na)<sup>+</sup>): 453.1445, found: 453.1486.

[0057]



Dipropyl


2-(1-(4-fluorophenyl)-3-oxo-3-phenylpropyl)malonate (table 3, entry 3)

It was synthesized in accordance with the above-mentioned manipulation.

40 Yield 92%, White solid, Mp 35-38 °C; IR [cm<sup>-1</sup>] (neat): 1733, 1687, 1510, 1226, 1161, 739; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.91-7.87 (m, 2H; Ar), 7.52 (appearance of br t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 1H; Ar), 7.42 (t, <sup>3</sup>J<sub>HH</sub> = 7.8 Hz, 2H; Ar), 7.27-7.23 (m, 2H; Ar), 6.92 (appearance of br t, <sup>3</sup>J<sub>HH</sub> = 8.7 Hz, 2H; Ar), 4.20-4.06 (m, 3H; CH, OCH<sub>2</sub>), 3.87 (t, <sup>3</sup>J<sub>HH</sub> = 6.8 Hz, 2H; OCH<sub>2</sub>), 3.82 (d, <sup>3</sup>J<sub>HH</sub> = 9.6 Hz, 1H; CH), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.53, δ<sub>B</sub> = 3.44, <sup>2</sup>J<sub>AB</sub> = 16.6, <sup>3</sup>J<sub>AM</sub> = 4.3, <sup>3</sup>J<sub>BM</sub> = 9.6 Hz, 2H; CH<sub>2</sub>), 1.64 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.0 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.50-1.40 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.91 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>), 0.79 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 197.4, 168.3, 167.8, 161.8 (d, J<sub>CF</sub> = 245.4 Hz), 136.8, 136.3, 133.1, 129.9 (d, J<sub>CF</sub> = 7.9 Hz), 128.6, 128.1, 115.2 (d, J<sub>CF</sub> = 21.2 Hz), 67.3, 67.0, 57.6, 42.6, 40.1, 21.8, 21.7, 10.3, 10.2; HPLC (Chiracel OJ-H, hexane/*i*-propanol = 19/1, flow rate 0.3 mL/min, λ = 254 nm): t<sub>major</sub> = 50.7 min, t<sub>minor</sub> = 63.1 min, ee = 98%; [α]<sub>D</sub><sup>21</sup> = +25.21 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>24</sub>H<sub>27</sub>FO<sub>5</sub>Na ((M+Na)<sup>+</sup>): 437.1740, found: 437.1728

[0058]

55



Dipropyl


2-(1-(4-methoxyphenyl)-3-oxo-3-phenylpropyl)malonate (table 3, entry 4)

It was synthesized in accordance with the above-mentioned manipulation.

15 Yield 80%, White solid, Mp 41-44 °C; IR [cm<sup>-1</sup>] (KBr): 1729, 1678, 1511, 1243, 1162; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.89 (br d, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; Ar), 7.50 (appearance of br t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 1H; Ar), 7.40 (t, <sup>3</sup>J<sub>HH</sub> = 7.8 Hz, 2H; Ar), 7.17 (d, <sup>3</sup>J<sub>HH</sub> = 8.7 Hz, 2H; Ar), 6.76 (d, <sup>3</sup>J<sub>HH</sub> = 8.5 Hz, 2H; Ar), 4.16-4.05 (m, 3H; CH, OCH<sub>2</sub>), 3.86 (t, <sup>3</sup>J<sub>HH</sub> = 6.6 Hz, 2H; OCH<sub>2</sub>), 3.82 (d, <sup>3</sup>J<sub>HH</sub> = 9.6 Hz, 1H; CH), 3.72 (s, 3H; OCH<sub>3</sub>), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.51, δ<sub>B</sub> = 3.42, <sup>2</sup>J<sub>AB</sub> = 16.5, <sup>3</sup>J<sub>AM</sub> = 4.2, <sup>3</sup>J<sub>BM</sub> = 9.5 Hz, 2H; CH<sub>2</sub>), 1.64 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.50-1.40 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.91 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>), 0.79 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 197.7, 168.5, 167.9, 158.6, 136.9, 133.0, 132.5, 129.2, 128.5, 128.1, 113.8, 67.2, 66.9, 57.8, 55.1, 42.8, 40.2, 21.8, 21.7, 10.3, 10.2; HPLC (Chiracel OJ-H, hexane/*i*-propanol = 9/1, flow rate 1.5 mL/min, λ = 254 nm): t<sub>major</sub> = 17.6 min, t<sub>minor</sub> = 11.0 min, ee > 99%; [α]<sub>D</sub><sup>21</sup> = +17.51 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>25</sub>H<sub>30</sub>O<sub>6</sub>Na ((M+Na)<sup>+</sup>): 449.1940, found: 449.1939.

20

25

**[0059]**

Dipropyl

2-(1-(4-nitrophenyl)-3-oxo-3-phenylpropyl)malonate (table 3, entry 5)


It was synthesized in accordance with the above-mentioned manipulation.

40 Yield 98%, White solid, Mp 82-86 °C; IR [cm<sup>-1</sup>] (KBr): 1726, 1686, 1519, 1346, 1239, 1151; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 8.12-8.09 (m, 2H; Ar), 7.90-7.87 (m, 2H; Ar), 7.56-7.49 (m, 3H; Ar), 7.45-7.41 (m, 2H; Ar), 4.31 (t d, <sup>3</sup>J<sub>HH</sub> = 4.3, <sup>3</sup>J<sub>HH</sub> = 9.4 Hz, 1H; CH), 4.17-4.07 (m, 2H; OCH<sub>2</sub>), 3.93-3.86 (m, 3H; CH, OCH<sub>2</sub>), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.61, δ<sub>B</sub> = 3.55, <sup>3</sup>J<sub>AB</sub> = 17.3, <sup>3</sup>J<sub>AM</sub> = 4.2, <sup>3</sup>J<sub>BM</sub> = 9.5 Hz, 2H; CH<sub>2</sub>), 1.64 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.0 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.52-1.43 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.91 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>), 0.80 (t, <sup>3</sup>J<sub>HH</sub> = 7.4 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 196.8, 167.9, 167.4, 148.6, 147.0, 136.5, 133.4, 129.4, 128.7, 128.0, 123.6, 67.5, 67.3, 56.9, 42.0, 40.4, 21.8, 21.7, 10.2, 10.2; HPLC (Chiracel OJ-H, hexane/*i*-propanol = 9/1, flow rate 1.0 mL/min, λ = 254 nm): t<sub>major</sub> = 28.5 min, t<sub>minor</sub> = 41.2 min, ee = 96%; [α]<sub>D</sub><sup>22</sup> = +31.37 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>24</sub>H<sub>27</sub>NO<sub>7</sub>Na ((M+Na)<sup>+</sup>): 464.1685, found: 464.1644.

45

50

**[0060]**



Dipropyl 2-(1-(3-nitrophenyl)-3-oxo-3-phenylpropyl)malonate (table 3, entry 6)


It was synthesized in accordance with the above-mentioned manipulation.

Yield 94%, Colorless liquid; IR [cm<sup>-1</sup>] (neat): 1731, 1686, 1638, 1532, 1352, 1265, 738; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>; TMS): δ = 8.18 (t, J<sub>HH</sub> = 1.9 Hz, 1H; Ar), 8.04 (d d, J<sub>HH</sub> = 1.8 Hz, J<sub>HH</sub> = 8.2 Hz, 1H; Ar), 7.89 (br d, J<sub>HH</sub> = 7.2 Hz, 2H; Ar), 7.71 (br d, J<sub>HH</sub> = 7.8 Hz, 1H; Ar), 7.54 ((br t, J<sub>HH</sub> = 7.3 Hz, 1H; Ar), 7.46-7.41 (m, 3H; Ar), 4.32 (t d, <sup>3</sup>J<sub>HH</sub> = 4.3, <sup>3</sup>J<sub>HH</sub> = 9.3 Hz, 1H; CH), 4.17-4.08 (m, 2H; OCH<sub>2</sub>), 3.92-3.88 (m, 3H; CH, OCH<sub>2</sub>), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.63, δ<sub>B</sub> = 3.57, <sup>2</sup>J<sub>AB</sub> = 17.4, <sup>3</sup>J<sub>AM</sub> = 4.4, <sup>3</sup>J<sub>BM</sub> = 9.4 Hz, 2H; CH<sub>2</sub>), 1.64 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.52-1.41 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.91 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>), 0.79 (t, <sup>3</sup>J<sub>HH</sub> = 7.4 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 196.9, 168.0, 167.5, 148.2, 143.1, 136.5, 135.3, 133.4, 129.3, 128.7, 128.0, 123.1, 122.2, 67.5, 67.2, 57.0, 42.1, 40.2, 21.8, 21.7, 10.2, 10.1; HPLC (Chiralpak AD-H, hexane/i-propanol = 9/1, flow rate 1.0 mL/min, λ = 254 nm): t<sub>major</sub> = 48.9 min, t<sub>minor</sub> = 32.1 min, ee = 94%; [α]<sub>D</sub><sup>23</sup> = +31.81 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>24</sub>H<sub>27</sub>NO<sub>7</sub>Na ((M+Na)<sup>+</sup>): 464.1685, found: 464.1658.

15

20

[0061]



Dipropyl

2-(1,3-bis(4-fluorophenyl)-3-oxopropyl)malonate (table 3, entry 7)

It was synthesized in accordance with the above-mentioned manipulation.


Yield 91%, Colorless liquid; IR [cm<sup>-1</sup>] (neat): 1732, 1686, 1600, 1510, 1228, 1157; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.94-7.91 (m, 2H; Ar), 7.26-7.22 (m, 2H; Ar), 7.11-7.06 (m, 2H; Ar), 6.95-6.90 (m, 2H; Ar), 4.18-4.06 (m, 3H; CH, OCH<sub>2</sub>), 3.86 (t, <sup>3</sup>J<sub>HH</sub> = 6.6 Hz, 2H; OCH<sub>2</sub>), 3.81 (d, <sup>3</sup>J<sub>HH</sub> = 9.6 Hz, 1H; CH), 3.72 (s, 3H; OCH<sub>3</sub>), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.50, δ<sub>B</sub> = 3.38, <sup>2</sup>J<sub>AB</sub> = 16.4, <sup>3</sup>J<sub>AM</sub> = 4.2, <sup>3</sup>J<sub>BM</sub> = 9.6 Hz, 2H; CH<sub>2</sub>), 1.64 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.50-1.40 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.91 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>), 0.79 (t, <sup>3</sup>J<sub>HH</sub> = 7.4 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 195.9, 168.4, 167.8, 165.8 (d, J<sub>CF</sub> = 254.7 Hz), 161.7 (d, J<sub>CF</sub> = 245.7 Hz), 136.1, 133.2, 130.8 (d, J<sub>CF</sub> = 9.0 Hz), 129.9 (d, J<sub>CF</sub> = 7.9 Hz), 115.7 (d, J<sub>CF</sub> = 21.8 Hz), 115.3 (d, J<sub>CF</sub> = 21.3 Hz), 67.3, 67.1, 57.6, 42.6, 40.2, 21.9, 21.7, 10.3, 10.2; HPLC (Chiralpak AS-H, hexane/i-propanol = 9/1, flow rate 0.5 mL/min, λ = 254 nm): t<sub>major</sub> = 20.3 min, t<sub>minor</sub> = 23.4 min, ee = 96%; [α]<sub>D</sub><sup>22</sup> = +21.56 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>24</sub>H<sub>26</sub>F<sub>2</sub>O<sub>5</sub>Na ((M+Na)<sup>+</sup>): 455.1646, found: 455.1668.

40

45

50

[0062]




Dipropyl

2-(3-(4-fluorophenyl)-1-(4-methoxyphenyl)-3-oxopropyl)malonate (table 3, entry 8)

15 It was synthesized in accordance with the above-mentioned manipulation.

Yield 81%, White solid, Mp 60-63 °C; IR [cm<sup>-1</sup>] (neat): 1731, 1686, 1599, 1514, 1266, 1251, 1157, 739; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ=7.94-7.91 (m, 2H; Ar), 7.18-7.15 (m, 2H; Ar), 7.07 (appearance of br t, <sup>3</sup>J<sub>HH</sub> = 8.6 Hz, 2H; Ar), 6.78-6.75 (m, 2H; Ar), 4.15-4.05 (m, 3H; CH, OCH<sub>2</sub>), 3.87 (t, <sup>3</sup>J<sub>HH</sub> = 6.7 Hz, 2H; OCH<sub>2</sub>), 3.82 (d, <sup>3</sup>J<sub>HH</sub> = 9.6 Hz, 1H; CH), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.53, δ<sub>B</sub> = 3.40, <sup>2</sup>J<sub>AB</sub> = 16.7, <sup>3</sup>J<sub>AM</sub> = 4.3, <sup>3</sup>J<sub>BM</sub> = 9.6 Hz, 2H; CH<sub>2</sub>), 1.68-1.61 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.50-1.40 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.91 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>), 0.79 (t, <sup>3</sup>J<sub>HH</sub> = 7.4 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 196.2, 168.6, 167.9, 165.7 (d, J<sub>CF</sub> = 254.6 Hz), 158.6, 133.4, 132.3, 130.8 (d, J<sub>CF</sub> = 9.2 Hz), 129.2, 115.6 (d, J<sub>CF</sub> = 21.8 Hz), 113.9, 67.2, 67.0, 57.8, 55.1, 42.7, 40.3, 21.9, 21.7, 10.3, 10.2; HPLC (Chiracel OD-H, hexane/*i*-propanol = 19/1, flow rate 0.5 mL/min, λ = 254 nm): t<sub>major</sub> = 33.0 min, t<sub>minor</sub> = 29.4 min, ee > 99%; [α]<sub>D</sub><sup>21</sup> = +16.28 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>25</sub>H<sub>29</sub>FO<sub>6</sub>Na ((M+Na)<sup>+</sup>): 467.1846, found: 467.1852.

25 **[0063]**



40 Dipropyl


2-(1-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)-3-oxopropyl)malonate (table 3, entry 9)

It was synthesized in accordance with the above-mentioned manipulation.

Yield 61%, Colorless liquid; IR [cm<sup>-1</sup>] (neat): 1728, 1686, 1598, 1519, 1265, 746, 705; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.95-7.91 (m, 2H; Ar), 7.11-7.06 (m, 2H; Ar), 6.79-6.72 (m, 3H; Ar), 4.16-4.05 (m, 3H; CH, OCH<sub>2</sub>), 3.88 (t, <sup>3</sup>J<sub>HH</sub> = 6.6 Hz, 2H; OCH<sub>2</sub>), 3.84 (d, <sup>3</sup>J<sub>HH</sub> = 9.6 Hz, 1H; CH), 3.82 (s, 3H; OCH<sub>3</sub>), 3.80 (s, 3H; OCH<sub>3</sub>), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.50, δ<sub>B</sub> = 3.39, <sup>2</sup>J<sub>AB</sub> = 16.3, <sup>3</sup>J<sub>AM</sub> = 4.3, <sup>3</sup>J<sub>BM</sub> = 9.4 Hz, 2H; CH<sub>2</sub>), 1.64 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.51-1.41 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.91 (t, <sup>3</sup>J<sub>HH</sub> = 7.4 Hz, 3H; CH<sub>3</sub>), 0.80 (t, <sup>3</sup>J<sub>HH</sub> = 7.4 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 196.3, 168.5, 167.9, 165.7 (d, J<sub>CF</sub> = 254.8 Hz), 148.7, 148.1, 133.4, 132.9, 130.8 (d, J<sub>CF</sub> = 9.2 Hz), 120.0, 115.6 (d, J<sub>CF</sub> = 21.8 Hz), 111.9, 111.2, 67.2, 67.0, 57.7, 55.9, 55.8, 42.7, 40.7, 21.9, 21.7, 10.3, 10.2; HPLC (Chiralpak AS-H, hexane/*i*-propanol = 9/1, flow rate 1.0 mL/min, λ = 254 nm): t<sub>major</sub> = 16.4 min, t<sub>minor</sub> = 14.0 min, ee = 96%; [α]<sub>D</sub><sup>22</sup> = +17.02 (c = 0.8 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>26</sub>H<sub>31</sub>FO<sub>7</sub>Na ((M+Na)<sup>+</sup>): 497.1951, found: 497.1966.

50 **[0064]**

55




Dipropyl

2-(1-(4-chlorophenyl)-3-(4-fluorophenyl)-3-oxopropyl)malonate (table 3, entry 10)

15 It was synthesized in accordance with the above-mentioned manipulation.

Yield 97%, White solid, Mp 69-71 °C; IR [cm<sup>-1</sup>] (KBr): 1730, 1685, 1600, 1300, 1238, 1157; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.94-7.90 (m, 2H; Ar), 7.21 (br s, 4H; Ar), 7.11-7.07 (m, 2H; Ar), 4.17-4.05 (m, 3H; CH, OCH<sub>2</sub>), 3.88 (t, <sup>3</sup>J<sub>HH</sub> = 6.7 Hz, 2H; OCH<sub>2</sub>), 3.82 (d, <sup>3</sup>J<sub>HH</sub> = 9.6 Hz, 1H; CH), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.53, δ<sub>B</sub> = 3.41, <sup>2</sup>J<sub>AB</sub> = 16.6, <sup>3</sup>J<sub>AM</sub> = 4.2, <sup>3</sup>J<sub>BM</sub> = 9.6 Hz, 2H; CH<sub>2</sub>), 1.64 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.51-1.41 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.91 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>), 0.78 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 195.7, 168.3, 167.7, 165.8 (d, J<sub>CF</sub> = 255.0 Hz), 139.0, 133.2, 133.0, 130.8 (d, J<sub>CF</sub> = 9.1 Hz), 129.7, 128.6, 115.7 (d, J<sub>CF</sub> = 21.9 Hz), 67.3, 67.1, 57.3, 42.3, 21.8, 21.7, 10.2, 10.2; HPLC (Chiracel OD-H, hexane/i-propanol = 19/1, flow rate 0.5 mL/min, λ = 254 nm): t<sub>major</sub> = 22.8 min, t<sub>minor</sub> = 20.1 min, ee = 97%; [α]<sub>D</sub><sup>20</sup> = +20.30 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd, for C<sub>24</sub>H<sub>26</sub>ClFO<sub>5</sub>Na ((M+Na)<sup>+</sup>): 471.1350, found: 471.1350.

25 **[0065]**



Dipropyl


2-(1-(2-chlorophenyl)-3-(4-fluorophenyl)-3-oxopropyl)malonate (table 3, entry 11)

40 It was synthesized in accordance with the above-mentioned manipulation.

Yield 80%, Colorless liquid; IR [cm<sup>-1</sup>] (neat): 1732, 1686, 1599, 1265, 1232, 1156, 738, 705; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.97-7.94 (m, 2H; Ar), 7.34-7.28 (m, 2H; Ar), 7.16-7.06 (m, 4H; Ar), 4.64 (t d, <sup>3</sup>J<sub>HH</sub> = 5.5, <sup>3</sup>J<sub>HH</sub> = 8.3 Hz, 1H; CH), 4.12-4.01 (m, 3H; CH, OCH<sub>2</sub>), 3.94 (t, <sup>3</sup>J<sub>HH</sub> = 6.6 Hz, 2H; OCH<sub>2</sub>), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.64, δ<sub>B</sub> = 3.60, <sup>2</sup>J<sub>AB</sub> = 16.7, <sup>3</sup>J<sub>AM</sub> = 8.1, <sup>3</sup>J<sub>BM</sub> = 5.1 Hz, 2H; CH<sub>2</sub>), 1.60 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.55-1.45 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.87 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>), 0.83 (t, <sup>3</sup>J<sub>HH</sub> = 7.4 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 196.0, 168.4, 167.9, 165.7 (d, J<sub>CF</sub> = 254.8 Hz), 137.7, 134.1, 133.3, 130.8 (d, J<sub>CF</sub> = 9.3 Hz), 130.1, 129.3, 128.3, 126.8, 115.6 (d, J<sub>CF</sub> = 21.8 Hz), 67.2, 67.1, 55.2, 40.4, 37.5, 21.8, 21.7, 10.2, 10.2; HPLC (Chiralpak AD-H, hexane/i-propanol = 9/1, flow rate 1.0 mL/min, λ = 254 nm): t<sub>major</sub> = 39.9 min, t<sub>minor</sub> = 16.8 min, ee = 93%; [α]<sub>D</sub><sup>22</sup> = +35.13 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd, for C<sub>24</sub>H<sub>26</sub>ClFO<sub>5</sub>Na ((M+Na)<sup>+</sup>): 471.1350, found: 471.1335.

50 **[0066]**

EP 2 258 477 A1




Dipropyl

2-(1-(4-fluorophenyl)-3-oxo-3-propylpropyl)malonate (table 3, entry 12)

It was synthesized in accordance with the above-mentioned manipulation.

15 Yield 90%, White solid, Mp 64-67 °C; IR [cm<sup>-1</sup>] (KBr): 1727, 1673, 1606, 1513, 1296, 1242, 836; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.78 (d, <sup>3</sup>J<sub>HH</sub> = 8.2 Hz, 2H; Ar), 7.27-7.20 (m, 4H; Ar), 6.93-6.89 (m, 2H; Ar), 4.20-4.05 (m, 3H; CH, OCH<sub>2</sub>), 3.86 (t, <sup>3</sup>J<sub>HH</sub> = 6.6 Hz, 2H; OCH<sub>2</sub>), 3.82 (d, <sup>3</sup>J<sub>HH</sub> = 9.6 Hz, 1H; CH), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.49, δ<sub>B</sub> = 3.41, <sup>2</sup>J<sub>AB</sub> = 16.6, <sup>3</sup>J<sub>AM</sub> = 4.2, <sup>3</sup>J<sub>BM</sub> = 9.5 Hz, 2H; CH<sub>2</sub>), 2.37 (s, 3H; CH<sub>3</sub>), 1.64 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.49-1.40 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.91 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>), 0.79 (t, <sup>3</sup>J<sub>HH</sub> = 7.4 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 197.0, 168.3, 167.8, 161.8 (d, J<sub>CF</sub> = 245.3 Hz), 143.9, 136.3, 134.3, 129.9 (d, J<sub>CF</sub> = 7.6 Hz), 129.2, 128.2, 115.2 (d, J<sub>CF</sub> = 21.3 Hz), 67.2, 67.0, 57.6, 42.4, 40.2, 21.8, 21.6, 21.5, 10.2, 10.1; HPLC (Chiralpak AS-H, hexane/*i*-propanol = 9/1, flow rate 0.5 mL/min, λ = 254 nm): t<sub>major</sub> = 30.8 min, t<sub>minor</sub> = 33.5 min, ee = 98%; [α]<sub>D</sub><sup>21</sup> = +24.25 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>25</sub>H<sub>29</sub>FO<sub>5</sub>Na ((M+Na)<sup>+</sup>): 451.1897, found: 451.1859.

25 [0067]



Dipropyl

2-(3-(4-chlorophenyl)-3-oxo-1-phenylpropyl)malonate (table 3, entry 13)


It was synthesized in accordance with the above-mentioned manipulation.

40 Yield 98%, Colorless liquid; IR [cm<sup>-1</sup>] (neat): 1731, 1687, 1589, 1265, 743, 703; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.84-7.81 (m, 2H; Ar), 7.39-7.36 (m, 2H; Ar), 7.26-7.21 (m, 4H; Ar), 7.17-7.14 (m, 1H; Ar), 4.18-4.05 (m, 3H; CH, OCH<sub>2</sub>), 3.87-3.84 (m, 3H; CH, OCH<sub>2</sub>), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.53, δ<sub>B</sub> = 3.42, <sup>2</sup>J<sub>AB</sub> = 16.6, <sup>3</sup>J<sub>AM</sub> = 4.4, <sup>3</sup>J<sub>BM</sub> = 9.4 Hz, 2H; CH<sub>2</sub>), 1.63 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.0 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.47-1.38 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.90 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>), 0.77 (t, <sup>3</sup>J<sub>HH</sub> = 7.4 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 196.5, 168.5, 167.8, 140.3, 139.4, 135.2, 129.6, 128.8, 128.5, 128.2, 127.2, 67.2, 67.0, 57.5, 42.6, 40.9, 21.8, 21.6, 10.3, 10.2; HPLC (2 x Chiracel OJ-H, hexane/*i*-propanol = 9/1, flow rate 0.5 mL/min, λ = 254 nm): t<sub>major</sub> = 76.2 min, t<sub>minor</sub> = 68.8 min, ee = 99%; [α]<sub>D</sub><sup>21</sup> = +17.53 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>24</sub>H<sub>27</sub>ClO<sub>5</sub>Na ((M+Na)<sup>+</sup>): 453.1445, found: 453.1418.

50 [0068]

55





Dipropyl


2-(3-(4-fluorophenyl)-3-oxo-1-phenylpropyl)malonate (table 3, entry 14)

It was synthesized in accordance with the above-mentioned manipulation.

15 Yield 92%, Colorless liquid; IR [cm<sup>-1</sup>] (neat): 1731, 1686, 1599, 1265, 1157, 745, 703; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.94-7.90 (m, 2H; Ar), 7.27-7.21 (m, 4H; Ar), 7.18-7.14 (m, 1H; Ar), 7.09-7.05 (m, 2H; Ar), 4.19-4.05 (m, 3H; CH, OCH<sub>2</sub>), 3.87-3.83 (m, 3H; CH, OCH<sub>2</sub>), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.53, δ<sub>B</sub> = 3.43, <sup>2</sup>J<sub>AB</sub> = 16.5, <sup>3</sup>J<sub>AM</sub> = 4.3, <sup>3</sup>J<sub>BM</sub> = 9.5 Hz, 2H; CH<sub>2</sub>), 1.63 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.0 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.47-1.38 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.90 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>), 0.77 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 196.1, 168.5, 167.8, 165.7 (d, J<sub>CF</sub> = 254.5 Hz), 140.4, 133.3, 130.8 (d, J<sub>CF</sub> = 9.2 Hz), 128.5, 128.2, 127.2, 115.6 (d, J<sub>CF</sub> = 21.9 Hz), 67.2, 67.0, 57.6, 42.5, 40.9, 21.8, 21.7, 10.3, 10.2; HPLC (Chiracel OJ-H, hexane/*i*-propanol = 19/1, flow rate 0.5 mL/min, λ = 254 nm): t<sub>major</sub> = 41.0 min, t<sub>minor</sub> = 56.7 min, ee = 99%; [α]<sub>D</sub><sup>22</sup> = +21.69 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>24</sub>H<sub>27</sub>FO<sub>5</sub>Na ((M+Na)<sup>+</sup>): 437.1740, found: 437.1729.

20

[0069]



Dipropyl

2-(3-(4-methoxyphenyl)-3-oxo-1-phenylpropyl)malonate (table 3, entry 15)


It was synthesized in accordance with the above-mentioned manipulation.

35 Yield 85%, White solid, Mp 63-65 °C; IR [cm<sup>-1</sup>] (neat): 1731, 1677, 1602, 1265, 1171, 739, 702; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.89-7.86 (m, 2H; Ar), 7.27-7.20 (m, 4H; Ar), 7.16-7.12 (m, 1H; Ar), 6.89-6.86 (m, 2H; Ar), 4.17 (t d, <sup>3</sup>J<sub>HH</sub> = 4.6, <sup>3</sup>J<sub>HH</sub> = 9.5 Hz, 1H; CH), 4.14-4.05 (m, 2H; OCH<sub>2</sub>), 3.87-3.83 (m, 3H; CH, OCH<sub>2</sub>), 3.82 (s, 3H; OCH<sub>3</sub>), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.45, δ<sub>B</sub> = 3.40, <sup>2</sup>J<sub>AB</sub> = 16.3, <sup>3</sup>J<sub>AM</sub> = 4.5, <sup>3</sup>J<sub>BM</sub> = 9.4 Hz, 2H; CH<sub>2</sub>), 1.63 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.47-1.37 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.90 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>), 0.77 (t, <sup>3</sup>J<sub>HH</sub> = 7.4 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 196.1, 168.5, 167.9, 163.4, 140.6, 130.4, 130.0, 128.4, 128.2, 127.1, 113.7, 67.2, 66.9, 57.7, 55.4, 42.3, 41.0, 21.8, 21.6, 10.3, 10.2; HPLC (Chiracel OD-H, hexane/*i*-propanol = 19/1, flow rate 0.5 mL/min, λ = 254 nm): t<sub>major</sub> = 40.4 min, t<sub>minor</sub> = 47.3 min, ee = 99%; [δ]<sub>D</sub><sup>20</sup> = +20.73 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>25</sub>H<sub>30</sub>O<sub>6</sub>Na ((M+Na)<sup>+</sup>): 449.1940, found: 449.1944.

40

45

[0070]




## Dipropyl

2-(3-oxo-1,3-di(thiophen-2-yl)propyl)malonate (table 3, entry 16)

It was synthesized in accordance with the above-mentioned manipulation.

Yield 73%, Beige liquid; IR [cm<sup>-1</sup>] (neat): 1734, 1663, 1416, 1265, 736, 704; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.75-7.73 (m, 1H; Ar), 7.61-7.58 (m, 1H; Ar), 7.11-7.08 (m, 2H; Ar), 6.93-6.91 (m, 1H; Ar), 6.86-6.83 (m, 1H; Ar), 4.53-4.48 (m, 1H; CH), 4.14-4.05 (m, 2H; OCH<sub>2</sub>), 3.99-3.93 (m, 2H; OCH<sub>2</sub>), 3.90 (d, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 1H; CH), 3.48 (d, <sup>3</sup>J<sub>HH</sub> = 6.8 Hz, 2H; CH<sub>2</sub>), 1.64 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.56-1.48 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.91 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>), 0.84 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 190.1, 168.1, 167.7, 144.1, 143.3, 133.8, 132.1, 128.1, 126.6, 125.9, 124.2, 67.3, 67.2, 57.8, 43.8, 36.3, 21.8, 21.7, 10.3, 10.2; HPLC (Chiralpak AS-H, hexane/*i*-propanol = 9/1, flow rate 1.0 mL/min, λ = 254 nm): t<sub>major</sub> = 12.7 min, t<sub>minor</sub> = 17.3 min, ee = 97%; [α]<sub>D</sub><sup>21</sup> = +22.21 (c = 1.0 in CHCl<sub>3</sub>), ESI-HRMS (m/z) calcd. for C<sub>20</sub>H<sub>24</sub>O<sub>5</sub>S<sub>2</sub>Na ((M+Na)<sup>+</sup>): 431.0963, found: 431.0922.

[0071]




## Dipropyl

2-(1-(5-methylfuran-2-yl)-3-oxo-3-phenylpropyl)malonate (table 3, entry 17)

It was synthesized in accordance with the above-mentioned manipulation.

Yield 71%, Yellow liquid; IR [cm<sup>-1</sup>] (neat): 1735, 1686, 1265, 750; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.95 (br d, J<sub>HH</sub> = 7.4 Hz, 2H; Ar), 7.58-7.51 (m, 1H; Ar), 7.47-7.41 (m, 2H; Ar), 5.95 (br s, 1H; Ar), 5.76 (br s, 1H; Ar), 4.29-4.23 (m, 1H; CH), 4.14-3.90 (m, 5H; CH, OCH<sub>2</sub>, OCH<sub>2</sub>), 3.58-3.41 (m, 2H; CH<sub>2</sub>), 2.17 (s, 3H, CH<sub>3</sub>), 1.68-1.53 (m, 4H; CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>), 0.95-0.85 (m, 6H; CH<sub>3</sub>, CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 197.5, 168.2, 168.0, 151.6, 151.0, 136.8, 133.1, 128.5, 128.1, 107.7, 106.1, 67.1, 67.1, 55.3, 39.8, 34.4, 21.8, 21.8, 13.5, 10.3, 10.3; HPLC (Chiralpak AD-H, hexane/*i*-propanol = 19/1, flow rate 0.5 mL/min, λ = 254 nm): t<sub>major</sub> = 40.8 min, t<sub>minor</sub> = 37.2 min, ee = 96%; [α]<sub>D</sub><sup>21</sup> = +9.82 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>23</sub>H<sub>28</sub>O<sub>6</sub>Na ((M+Na)<sup>+</sup>): 423.1784, found: 423.1777.

[0072]



## Dipropyl


2-(3-oxo-1-phenyl-3-(1H-pyrrol-1-yl)propyl)malonate (table 3, entry 18)

It was synthesized in accordance with the above-mentioned manipulation.

Yield 93%, White solid, Mp 88-91 °C; IR [cm<sup>-1</sup>] (KBr): 1716, 1471, 1280, 1229, 1172, 748; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.30-7.25 (m, 6H; Ar), 7.22-7.18 (m, 1H; Ar), 6.26-6.23 (m, 2H; Ar), 4.16-4.06 (m, 3H; CH, OCH<sub>2</sub>), 3.88-3.84 (m, 3H; CH, OCH<sub>2</sub>), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.45, δ<sub>B</sub> = 3.29, <sup>2</sup>J<sub>AB</sub> = 16.3, <sup>3</sup>J<sub>AM</sub> = 4.2, <sup>3</sup>J<sub>BM</sub> = 9.7 Hz, 2H; CH<sub>2</sub>), 1.64 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.2 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.48-1.39 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.90 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>), 0.78 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 168.3, 168.2, 167.6, 139.6, 128.6, 128.1, 127.5, 119.1, 113.1, 67.3, 67.1, 57.2, 41.1, 38.7, 21.8, 21.6, 10.2, 10.2; HPLC (Chiralpak AS-H, hexane/*i*-propanol = 19/1, flow rate 0.5 mL/min, λ = 254 nm): t<sub>major</sub> = 24.4 min, t<sub>minor</sub> = 31.2 min, ee = 99%; [α]<sub>D</sub><sup>20</sup> = +16.38 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>22</sub>H<sub>27</sub>NO<sub>5</sub>Na ((M+Na)<sup>+</sup>): 408.1787, found: 408.1755.

[0073]

EP 2 258 477 A1




Dipropyl

2-(3-oxo-1,5-diphenylpent-4-enyl)malonate (table 3, entry 19)

It was synthesized in accordance with the above-mentioned manipulation.

15 Yield 75%, White solid, Mp 69-73 °C; IR [cm<sup>-1</sup>] (KBr): 1731, 1646, 1227, 1163, 705; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.51-7.46 (m, 3H; Ar), 7.37-7.34 (m, 3H; Ar), 7.29-7.23 (m, 4H; Ar), 7.19-7.14 (m, 1H; Ar), 7.14 (d, <sup>3</sup>J<sub>HH</sub> = 16.4, 1H; Ar), 4.16-4.07 (m, 3H; CH, OCH<sub>2</sub>), 3.87-3.81 (m, 3H; CH, OCH<sub>2</sub>), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.20, δ<sub>B</sub> = 3.16, <sup>2</sup>J<sub>AB</sub> = 16.1, <sup>3</sup>J<sub>AM</sub> = 4.6, <sup>3</sup>J<sub>BM</sub> = 9.2 Hz, 2H; CH<sub>2</sub>), 1.65 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.48-1.38 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.92 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>), 0.77 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ = 197.4, 168.4, 167.8, 142.8, 140.4, 134.5, 130.4, 128.9, 128.4, 128.3, 128.2, 127.2, 126.0, 67.2, 66.9, 57.6, 44.8, 41.0, 21.9, 21.6, 10.3, 10.2; HPLC (Chiralpak AS-H, hexane/*i*-propanol = 9/1, flow rate 1.0 mL/min, λ = 254 nm): t<sub>major</sub> = 11.8 min, t<sub>minor</sub> = 14.4 min, ee = 86%; [α]<sub>D</sub><sup>22</sup> = +14.56 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>26</sub>H<sub>30</sub>O<sub>5</sub>Na ((M+Na)<sup>+</sup>): 445.1991, found: 445.1975.

[0074]



Dipropyl

2-(5-oxo-1,5-diphenylpent-1-en-3-yl)malonate (table 3, entry 20)

It was synthesized in accordance with the above-mentioned manipulation.

40 Yield 46%, White solid, Mp 42-45 °C; IR [cm<sup>-1</sup>] (KBr): 1728, 1682, 1234, 754, 692; <sup>1</sup>H NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ = 7.98-7.94 (m, 2H; Ar), 7.56-7.52 (m, 1H; Ar), 7.47-7.43 (m, 2H; Ar), 7.29-7.22 (m, 4H; Ar), 7.20-7.16 (m, 1H; Ar), 6.46 (d, <sup>3</sup>J<sub>HH</sub> = 15.8 Hz, 1H; Ar), 6.25 (dd, <sup>3</sup>J<sub>HH</sub> = 15.8, <sup>3</sup>J<sub>HH</sub> = 9.0 Hz, 1H; Ar), 4.15-4.00 (m, 4H; OCH<sub>2</sub>, OCH<sub>2</sub>), 3.78 (d, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 1H; CH), 3.73-3.67 (m, 1H; CH), ABM spin system (A = B = M = H, δ<sub>A</sub> = 3.40, δ<sub>B</sub> = 3.27, <sup>2</sup>J<sub>AB</sub> = 16.8, <sup>3</sup>J<sub>AM</sub> = 4.9, <sup>3</sup>J<sub>BM</sub> = 7.9 Hz, 2H; CH<sub>2</sub>), 1.68-1.55 (m, 4H; CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>), 0.92 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>), 0.87 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (124.5 MHz, CDCl<sub>3</sub>, TMS): δ = 198.0, 168.4, 168.3, 137.0, 136.9, 133.1, 132.6, 128.6, 128.5, 128.4, 128.2, 127.5, 126.4, 67.1, 67.0, 55.7, 41.3, 38.8, 21.9, 21.8, 10.3, 10.3; HPLC (Chiralpak AS-H, hexane/*i*-propanol = 40/1, flow rate 0.5 mL/min, λ = 254 nm): t<sub>major</sub> = 32.5 min, t<sub>minor</sub> = 38.0 min, ee = 97%; [α]<sub>D</sub><sup>21</sup> = +1.20 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>26</sub>H<sub>30</sub>O<sub>5</sub>Na ((M+Na)<sup>+</sup>): 445.1991, found: 445.1988, C<sub>26</sub>H<sub>31</sub>O<sub>5</sub> ((M+H)<sup>+</sup>): 423.2171, found: 423.2150.

[0075]

Table 1. Effect of metal sources and chiral ligands.<sup>a</sup>

5

10

entry	metal (x mol%)	ligand	solv.	time (h)	yield (%) <sup>b</sup>	ee (%) <sup>c</sup>
1 <sup>d</sup>	Ca(O- <i>i</i> -Pr) <sub>2</sub> (10%)	I	THF	24	47	4
2 <sup>d</sup>	Ca(O- <i>i</i> -Pr) <sub>2</sub> (10%)	II	THF	24	47	49
3 <sup>d</sup>	Ca(O- <i>i</i> -Pr) <sub>2</sub> (10%)	III	THF	24	89	52
4 <sup>e</sup>	Ca(O- <i>i</i> -Pr) <sub>2</sub> (5%)	III	Tol.	18	58	65
5 <sup>e</sup>	Sr(O- <i>i</i> -Pr) <sub>2</sub> (5%)	III	Tol.	18	91	97
6 <sup>e</sup>	Ba(O- <i>i</i> -Pr) <sub>2</sub> (5%)	III	Tol.	18	80	76
7 <sup>e</sup>	Ba(O- <i>t</i> -Bu) <sub>2</sub> (5%)	III	Tol.	18	82	70

15

20

25

30

II R = 4-tolyl  
III R = 2,5-dimethylbenzene


35

40

45

50

55

Table 2. Conjugate addition reactions of malonates **1a-f** to **2a**.<sup>a</sup>

entry	$\text{Sr(O-}i\text{-Pr)}_2$ (x mol%)	R	time (h)	yield (%) <sup>b</sup>	ee (%) <sup>c</sup> (configuration)
1	5	Me	24	65	94 (R) <sup>d</sup>
2	5	Et	18	91	97 (R) <sup>d</sup>
3	5	<i>n</i> -Pr	7	92	99
4	2.5	<i>n</i> -Pr		90	99
5 <sup>e</sup>	1	<i>n</i> -Pr	9	70	97
6 <sup>f</sup>	0.5	<i>n</i> -Pr	24	72	97
7	5	<i>i</i> -Pr	21	83	89
8	5	<i>n</i> -Bu	3	85	96
9	5	Bn	18	85	84

**Table 3.** Conjugate addition reactions of **1c** to enones **2b-u**.<sup>a</sup>

5

10

15

20

25

30

35

40

entry	R <sup>1</sup>	R <sup>2</sup>	adduct	yield (%) <sup>b</sup>	ee (%) <sup>c</sup>
1	2-ClC <sub>6</sub> H <sub>4</sub>	Ph	<b>3cb</b>	76	92
2	4-ClC <sub>6</sub> H <sub>4</sub>	Ph	<b>3cc</b>	93	97
3	4-FC <sub>6</sub> H <sub>4</sub>	Ph	<b>3cd</b>	92	98
4	4-MeOC <sub>6</sub> H <sub>4</sub>	Ph	<b>3ce</b>	80	>99
5	4-NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub>	Ph	<b>3cf</b>	98	96
6	3-NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub>	Ph	<b>3cg</b>	94	94
7	4-FC <sub>6</sub> H <sub>4</sub>	4-FC <sub>6</sub> H <sub>4</sub>	<b>3ch</b>	91	96
8	4-MeOC <sub>6</sub> H <sub>4</sub>	4-FC <sub>6</sub> H <sub>4</sub>	<b>3ci</b>	81	>99
9	3,4-di-MeOC <sub>6</sub> H <sub>3</sub>	4-FC <sub>6</sub> H <sub>4</sub>	<b>3cj</b>	61	96
10	4-ClC <sub>6</sub> H <sub>4</sub>	4-FC <sub>6</sub> H <sub>4</sub>	<b>3ck</b>	97	97
11	2-ClC <sub>6</sub> H <sub>4</sub>	4-FC <sub>6</sub> H <sub>4</sub>	<b>3cl</b>	80	93
12	4-FC <sub>6</sub> H <sub>4</sub>	4-MeC <sub>6</sub> H <sub>4</sub>	<b>3cm</b>	90	98
13	Ph	4-ClC <sub>6</sub> H <sub>4</sub>	<b>3cn</b>	98	99
14	Ph	4-FC <sub>6</sub> H <sub>4</sub>	<b>3co</b>	92	99
15	Ph	4-MeOC <sub>6</sub> H <sub>4</sub>	<b>3cp</b>	85	99
16	2-thienyl	2-thienyl	<b>3cq</b>	73	97
17 <sup>d</sup>	5-methylfuran-2-yl	Ph	<b>3cr</b>	71	96
18 <sup>e</sup>	Ph	1-pyrrolyl	<b>3cs</b>	90	>99
19 <sup>f</sup>	Ph	-CH=CHPh	<b>3ct</b>	97	86
20 <sup>f</sup>	-CH=CH- Ph	Ph	<b>3cu</b>	62	97

<sup>a</sup> See footnote in Table 1.<sup>b</sup> Isolated yields.<sup>c</sup> Determined by chiral HPLC analysis.<sup>d</sup> redaction time 48 h.<sup>e</sup> redaction time 24 h.<sup>f</sup> 2.2 equivalents of malonate **1c** were used.


[Michael addition to chalcone of a malonic ester]

**[0076]** 0.015 mmol of strontium hexamethyldisilazide (Sr(HMDS)<sub>2</sub>), 0.015 mmol of ligand, and 100 mg of molecular sieve 4A were suspended in 1 mL of toluene, and stirred for two hours at room temperature under an argon atmosphere. Thereafter, a toluene solution (1 mL) of 0.36 mmol of a malonic acid di-n-propyl ester, and a toluene solution of chalcone (0.3 mmol) were added. After the finishing of the reaction (the finishing of the reaction was confirmed by the thin-layer chromatography), a saturated ammonium chloride aqueous solution was added to the reaction solution. In addition, an organic phase was separated with dichloromethane. And a water phase was extracted with dichloromethane. The organic phase was collected and dried over anhydrous sodium sulfate. Thereafter, sodium sulfate was filtered off, and the solvent was removed by the distillation under reduced pressure. And the crude refined product was refined with the preparative thin-layer chromatography.

**[0077]** An enantiometric excess of the target product (refined product) obtained in such a manner was determined with a high performance liquid chromatography.

**[0078]** Additionally, Sr(HMDS)<sub>2</sub> was synthesized with the method (Inorg. Chem., 1991, 30, 96-101) reported by Wast-erhausen. Ligand was synthesized with method (J. Am. Chem. Soc., 1997, 119, 6452-6453) reported by Evans. Chalcones were procured from TOKYO CHEMICAL INDUSTRY CO., LTD. and Wako Pure Chemical industries, LTD.

**[0079]**



## Dipropyl

2-((1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)(phenyl)methyl)malonate (table 5): Colorless oil; IR [cm<sup>-1</sup>] (neat): 1747, 1731, 1682, 1600, 1455, 1266, 1221, 1155, 1059, 743, 702; NMR (600.2 MHz, CDCl<sub>3</sub>, TMS): δ= 8.01-7.97 (m, 1H; Ar), 7.41-7.37 (m, 1H; Ar), 7.32-7.11 (m, 7H; Ar), 4.98 (d, <sup>3</sup>J<sub>HH</sub> = 12.0 Hz, 1H; CH<sup>e</sup>), 4.14-4.00 (m, 2H; OCH<sub>2</sub>), 3.85-3.75 (m, 3H; CH<sup>d</sup>, CH<sub>2</sub>), 3.11 (d t, <sup>3</sup>J<sub>HH</sub> = 12.9, <sup>3</sup>J<sub>HH</sub> = 4.1 Hz, 1H; CH<sup>c</sup>), 2.99-2.92 (m, 1H; CH<sup>a</sup>), 2.86-2.81 (m, 1H; CH<sup>a</sup>), 2.15-2.10 (m, 1H; CH<sup>b</sup>), 1.86 (appearance q d, <sup>3</sup>J<sub>HH</sub> = 12.9, J<sub>HH</sub> = 4.2 Hz, 1H; CH<sup>b</sup>), 1.60 (appearance of sext, <sup>3</sup>J<sub>HH</sub> = 7.1 Hz, 2H; CH<sub>2</sub>CH<sub>3</sub>), 1.40-1.32 (m, 2H; CH<sub>2</sub>CH<sub>3</sub>), 0.89 (t, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 3H; CH<sub>3</sub>), 0.74 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 3H; CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (150.9 MHz, CDCl<sub>3</sub>, TMS): δ= 198.8, 169.2, 168.7, 143.6, 139.3, 133.3, 133.2, 129.5, 128.4, 128.2, 127.3, 127.0, 126.5, 67.0, 66.7, 54.9, 49.6, 47.7, 29.5, 27.8, 21.8, 21.6, 10.2, 10.2; HPLC (Chiralpak AS-H, hexane/*i*-propanol = 40/1, flow rate 0.5 mL/min, λ= 254 nm): t<sub>major</sub> = 16.5 min, t<sub>minor</sub> = 19.6 min, ee = 96%, t<sub>major</sub> = 23.3 min, t<sub>minor</sub> = 26.3 min; [α]<sub>D</sub><sup>21</sup> = + 59.52 (c = 1.0 in CHCl<sub>3</sub>); ESI-HRMS (m/z) calcd. for C<sub>26</sub>H<sub>30</sub>O<sub>5</sub>Na [(M+Na)<sup>+</sup>]: 445.1991, found: 445.2042.

5

10

15

20

25

30

35



40

45

50

55

Table 4




Strontiums	Catalyst amount (mole %)	Yield (%) <sup>[a]</sup>	Enantiometric excess (%) <sup>[b]</sup>
1 Sr(O- <i>i</i> -Pr) <sub>2</sub>	5	92	99
2 Sr(HMOS) <sub>2</sub>	5	97	99
3 Sr(HMDS) <sub>2</sub>	3	99	98
4 Sr(HMDS) <sub>2</sub>	2	96	96

<sup>[a]</sup>Isolated yield<sup>[b]</sup>Determined with chiral HPLC analysis



Table 5




Strontiums	Compound 1 (y equivalents)	Yield (%) <sup>[a]</sup>	Diastereomer ratio	Enantiometric excess (%) <sup>[b]</sup>
1 Sr(O- <i>i</i> -Pr) <sub>2</sub>	2.5	50	97:3	80
2 Sr(O- <i>i</i> -Pr) <sub>2</sub>	5	92	97:3	66
3 Sr(O- <i>i</i> -Pr) <sub>2</sub>	1.2	40	97:3	88
4 Sr(HMDS) <sub>2</sub>	1.2	38	97:3	95
5 Sr(HMDS) <sub>2</sub>	1.2	26	98:2	95
6 Sr(HMDS) <sub>2</sub>	2.5	50	97:3	94
7 Sr(HMDS) <sub>2</sub>	1.2	86	98:2	60

<sup>[a]</sup>Isolated yield

<sup>[b]</sup>Determined with chiral HPLC analysis

Table 6



Entry	Substituent R <sup>1</sup>	Substituent R <sup>2</sup>	Reaction time (time)	Yield (%) <sup>[a]</sup>	Enantioselectivity (%) <sup>[b]</sup>
1	2-Cl-C <sub>6</sub> H <sub>4</sub>	Ph	7	82	95
2	4-Cl-C <sub>6</sub> H <sub>4</sub>	Ph	7	93	97
3	2-Cl-C <sub>6</sub> H <sub>4</sub>	4-F-C <sub>6</sub> H <sub>4</sub>	7	92	93
4	Ph	-CH=CHPh	7	95	90
5	4-Cl-C <sub>6</sub> H <sub>4</sub>	4-F-C <sub>6</sub> H <sub>4</sub>	7	94	93
6	3-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Ph	7	86	96
7	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	Ph	7	81	97


<sup>[a]</sup>Isolated yield

<sup>[b]</sup>Determined with chiral HPLC analysis

## Claims

1. A catalyst configured using MX<sub>2</sub> (M is Be, Mg, Ca, Sr, Ba or Ra, and X is an arbitrary group) and a compound represented by the following general formula [I].


General formula [I]




[R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, and R<sup>10</sup> each represents a substituted cyclic group or an unsubstituted cyclic group. There are two cases for R<sup>9</sup> and R<sup>10</sup>, i.e. the case that they form a ring and the case that they do not form a ring.]

- 15
2. A catalyst according to claim 1, wherein said MX<sub>2</sub> is M(OR<sup>5</sup>)<sub>2</sub> (M is Mg, Ca, Sr or Ba. R<sup>5</sup> is an alkyl group).
3. A catalyst according to claim 1, wherein said MX<sub>2</sub> is M(OR<sup>5</sup>)<sub>2</sub> (M is Ca, Sr or Ba. R<sup>5</sup> is an alkyl group having a carbon number of 1 to 10).
- 20
4. A catalyst according to claim 1, wherein said MX<sub>2</sub> is Sr(OR<sup>5</sup>)<sub>2</sub> (R<sup>5</sup> is an alkyl group having a carbon number of 1 to 10).
5. A catalyst according to claim 1, wherein said X is an amide group.
- 25
6. A catalyst according to claim 1, wherein said X is hexamethyldisilazide.
7. A catalyst according to claim 1, wherein said cyclic group is an aromatic group.
8. A catalyst according to one of claim 1 to claim 7, wherein the compound represented by said general formula [I] and M of said compound MX<sub>2</sub> are coordinate-bonded to each other.
- 30
9. A catalyst according to one of claim 1 to claim 8, said catalyst used for a reaction between a compound represented by the following general formula [II] and a compound represented by the following general formula [III].

General formula [II]



General formula [III]




## EP 2 258 477 A1


[Each of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> is an arbitrary substituent. Each of W<sup>1</sup>, W<sup>2</sup>, and W<sup>3</sup> is an electron-withdrawing group.]

10. A catalyst according to claim 9, wherein each of said R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> is an H group or a hydrocarbon group.
- 5 11. A catalyst according to claim 9, wherein said electron-withdrawing group is an ester group or a carbonyl group.
12. A catalyst according to claim 9, wherein the compound represented by said general formula [II] is a dicarboxylate ester.
- 10 13. A catalyst according to claim 9, wherein the compound represented by said general formula [II] is a malonic ester.
14. A catalyst according to claim 9, wherein the compound represented by said general formula [III] is an enone.
15. A reaction method, comprising reacting a compound represented by the following general formula [II] with a compound represented by the following general formula [III] in the presence of any of the catalysts of claim 1 to claim 14.
- 15

General formula [II]



General formula [III]



[Each of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> is an arbitrary substituent. Each of W<sup>1</sup>, W<sup>2</sup>, and W<sup>3</sup> is an electron-withdrawing group.]


- 45 16. A reaction method according to claim 15, wherein each of said R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> is an H group or a hydrocarbon group.
17. A reaction method according to claim 15, wherein said electron-withdrawing group is an ester group or a carbonyl group.
- 50 18. A reaction method according to claim 15, wherein the compound represented by said general formula [II] is a dicarboxylate ester.
19. A reaction method according to claim 15, wherein the compound represented by said general formula [II] is a malonic ester.
- 55 20. A reaction method according to claim 15, wherein the compound represented by said general formula [III] is an enone.
21. A reaction method according to one of claim 15 to claim 20, wherein a molecular sieve is added to a solution of said

reaction.

22. A reaction method according to one of claim 15 to claim 21, wherein an aromatic hydrocarbon solvent is used as a solvent of said reaction.

23. A reaction method according to one of claim 15 to claim 22, said reaction method used for obtaining a compound represented by the following general formula [IV].


General formula [IV]



Amended claims under Art. 19.1 PCT


1. (Currently amended) A reaction method, comprising reacting a compound represented by the following general formula [II] with a compound represented by the following general formula [III] in the presence of a catalyst configured using  $MX_2$  (M is Be, Mg, Ca, Sr, Ba or Ra, and X is an arbitrary group) and a compound represented by the following general formula [I].


General formula [I]



[R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, and R<sup>10</sup> each represents a substituted cyclic group or a unsubstituted cyclic group. There are two cases for R<sup>9</sup> and R<sup>10</sup>, i.e. the case that they form a ring and the case that they do not form a ring.]


General formula [III]




General formula [III]

15 [Each of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> is an arbitrary substituent. Each of W<sup>1</sup>, W<sup>2</sup>, and W<sup>3</sup> is an electron-withdrawing group.]

- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55
2. (Currently amended) A reaction method according to claim 1, wherein said MX<sub>2</sub> is M(OR<sup>5</sup>)<sub>2</sub> (M is Mg, Ca, Sr or Ba. R<sup>5</sup> is an alkyl group).
  3. (Currently amended) A reaction method according to claim 1, wherein said MX<sub>2</sub> is M(OR<sup>5</sup>)<sub>2</sub> (M is Ca, Sr or Ba. R<sup>5</sup> is an alkyl group having a carbon number of 1 to 10).
  4. (Currently amended) A reaction method according to claim 1, wherein said MX<sub>2</sub> is Sr(OR<sup>5</sup>)<sub>2</sub> (R<sup>5</sup> is an alkyl group having a carbon number of 1 to 10).
  5. (Currently amended) A reaction method according to claim 1, wherein said X is an amide group.
  6. (Currently amended) A reaction method according to claim 1, wherein said X is hexamethyldisilazide.
  7. (Currently amended) A reaction method according to claim 1, wherein said cyclic group is an aromatic group.
  8. (Currently amended) A reaction method according to one of claim 1 to claim 7, wherein the compound represented by said general formula [I] and M of said compound MX<sub>2</sub> are coordinate-bonded to each other.
  9. (Currently amended) A reaction method according to claim 1, wherein each of said R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> is an H group or a hydrocarbon group.
  10. (Currently amended) A reaction method according to claim 1, wherein said electron-withdrawing group is an ester group or a carbonyl group.
  11. (Currently amended) A reaction method according to claim 1, wherein the compound represented by said general formula [II] is a dicarboxylate ester.
  12. (Currently amended) A reaction method according to claim 1, wherein the compound represented by said general formula [II] is a malonic ester.
  13. (Currently amended) A reaction method according to claim 1, wherein the compound represented by said general formula [III] is an enone.
  14. (Currently amended) A reaction method according to claim 1, wherein an aromatic hydrocarbon solvent is used as a solvent of said reaction.
  15. (Currently amended) A reaction method according to claim 1, said reaction method used for obtaining a compound represented by the following general formula [IV].



General formula [IV]

- 15
16. (Currently amended) A catalyst used for a reaction between a compound represented by the following general formula [I] and a compound represented by the following general formula [III], said catalyst configured using  $MX_2$  (M is Be, Mg, Ca, Sr, Ba or Ra, and X is an arbitrary group) and a compound represented by the following general formula [I].

General formula [I]

35


$R^7$ ,  $R^8$ ,  $R^9$ , and  $R^{10}$  each represents a substituted cyclic group or an unsubstituted cyclic group. There are two cases for  $R^9$  and  $R^{10}$ , i.e. the case that they form a ring and the case that they do not form a ring.]

General formula [III]General formula [III]

[Each of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> is an arbitrary substituent. Each of W<sup>1</sup>, W<sup>2</sup>, and W<sup>3</sup> is an electron-withdrawing group.]

17. (Currently amended) A catalyst configured using MX<sub>2</sub> (M is Ca, Sr, Ba or Ra, and X is an arbitrary group) and a compound represented by the following general formula [I].

General formula [I]



R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, and R<sup>10</sup> each represents a substituted cyclic group or an unsubstituted cyclic group. There are two cases for R<sup>9</sup> and R<sup>10</sup>, i.e. the case that they form a ring and the case that they do not form a ring.

18. (Currently amended) A catalyst according to claim 16 or claim 17, wherein said MX<sub>2</sub> is M(OR<sup>5</sup>)<sub>2</sub> (M is Ca, Sr or Ba. R<sup>5</sup> is an alkyl group).
19. (Currently amended) A catalyst according to claim 16 or claim 17, wherein said MX<sub>2</sub> is M(OR<sup>5</sup>)<sub>2</sub> (M is Ca, Sr or Ba. R<sup>5</sup> is an alkyl group having a carbon number of 1 to 10).
20. (Currently amended) A catalyst according to claim 16 or claim 17, wherein said MX<sub>2</sub> is Sr(OR<sup>5</sup>)<sub>2</sub> (R<sup>5</sup> is an alkyl group having a carbon number of 1 to 10).
21. (Currently amended) A catalyst according to claim 16 or claim 17, wherein said X is an amide group.
22. (Currently amended) A catalyst according to claim 16 or claim 17, wherein said X is hexamethyldisilazide.
23. (Currently amended) A catalyst according to claim 16 or claim 17, wherein said cyclic group is an aromatic group.
24. (New) A catalyst according to one of claim 16 to claim 23, wherein the compound represented by said general formula [I] and M of said compound MX<sub>2</sub> are coordinate-bonded to each other.
25. (New) A catalyst according to claim 16, wherein each of said R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> is an H group or a hydrocarbon group.
26. (New) A catalyst according to claim 16, wherein said electron-withdrawing group is an ester group or a carbonyl group.
27. (New) A catalyst according to claim 16, wherein the compound represented by said general formula [II] is a dicarboxylate ester.
28. (New) A catalyst according to claim 16, wherein the compound represented by said general formula [II] is a malonic ester.
29. (New) A catalyst according to claim 16, wherein the compound represented by said general formula [III] is an enone.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2009/051322

A. CLASSIFICATION OF SUBJECT MATTER		
B01J31/02(2006.01)i, C07C67/347(2006.01)i, C07C69/738(2006.01)i, C07C201/12 (2006.01)i, C07C205/56(2006.01)i, C07B53/00(2006.01)n, C07B61/00(2006.01)n,		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) B01J31/02, C07C67/347, C07C69/738, C07C201/12, C07C205/56, C07B53/00, C07B61/00, C07D207/325, C07D307/54, C07D333/24		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2009 Kokai Jitsuyo Shinan Koho 1971-2009 Toroku Jitsuyo Shinan Koho 1994-2009		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) JSTPlus (JDreamII), JST7580 (JDreamII)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	David A. EVANS, Scott G. NELSON, Chiral Magnesium Bis(sulfonamide) Complexes as Catalysts for the Merged Enolization and Enantioselective Amination of N-Acyloxazolidinones. A Catalytic Approach to the Synthesis of Arylglycines, J. Am. Chem. Soc., 1997.07.09, Vol.119, No.27, P.6452-6453	1-2, 7-8 3-6, 9-23
A	JP 2001-253844 A (Japan Science and Technology Corp.), 18 September, 2001 (18.09.01), Claim 1; Par. No. [0017] (Family: none)	1-23
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 02 March, 2009 (02.03.09)	Date of mailing of the international search report 17 March, 2009 (17.03.09)	
Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer	
Facsimile No.	Telephone No.	

Form PCT/ISA/210 (second sheet) (April 2007)



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2009/051322

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP 2004-269481 A (Kanto Chemical Co., Inc.), 30 September, 2004 (30.09.04), Claims 1 to 5; Par. Nos. [0012] to [0025] & US 2004/0176616 A1 & EP 1439159 A1	1-23
P,X P,A	Magno AGOSTINHO, Shu KOBAYASHI, Strontium- Catalyzed Highly Enantioselective Michael Additions of Malonates to Enones, J. Am. Chem. Soc., 2008.02.27, Vol.130, No.8, P.2430-2431	1-4, 7-23 5-6
P,X P,A	AGOSTINHO Magno, Shu KOBAYASHI, "Strontium Shokubai o Mochiiru Malonic Acid Ester no Enone eno Ko-Enantio Sentakuteki Michael Fuka Hanno", CSJ: The Chemical Society of Japan Koen Yokoshu, 12 March, 2008 (12.03.08), Vol.88, No.2, page 1270	1-4, 7-23 5-6

Form PCT/ISA/210 (continuation of second sheet) (April 2007)

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Non-patent literature cited in the description

- **Park, S.-Y. ; Morimoto, H. ; Matsunaga, S. ; Shibasaki, M.** *Tetrahedron Lett.*, 2007, vol. 48, 2815-2818 [0002]
- **Chen, C. ; Zhu, S.-F. ; Wu, X.-Y. ; Zhou, Q.-L.** *Tetrahedron: Asymmetry*, 2006, vol. 17, 2761-2767 [0002]
- **Kumaraswamy, G. ; Jena, N. ; Sastry, M. N. V. ; Rao, G. V. ; Ankamma, K.** *J. Mol. Catal. A*, 2005, vol. 230, 59-67 [0002]
- **Velmathi, S. ; Swarnalakshmi, S. ; Narasimhan, S.** *Tetrahedron: Asymmetry*, 2003, vol. 14, 113-117 [0002]
- **Annamalai, V. ; DiMauro, E. F. ; Carroll, P. J. ; Kozlowski, M. C.** *J. Org. Chem.*, 2003, vol. 68, 1973-1981 [0002]
- **Xu, Y. ; Ohori, K. ; Ohshima, T. ; Shibasaki, M.** *Tetrahedron*, 2002, vol. 58, 2585-2588 [0002]
- **Kumaraswamy, G. ; Sastry, M. N. V. ; Jena, N.** *Tetrahedron Lett.*, 2001, vol. 42, 8515-8517 [0002]
- **Kim, Y. S. ; Matsunaga, S. ; Das, J. ; Sekine, A. ; Ohshima, T. ; Shibasaki, M.** *J. Am. Chem. Soc.*, 2000, vol. 122, 6506-6507 [0002]
- **End, N. ; Macko, L. ; Zehnder, M. ; Pfaltz, A.** *Chem. Eur. J.*, 1998, vol. 4, 818-824 [0002]
- **Manickam, G. ; Sundararajan, G.** *Tetrahedron: Asymmetry*, 1997, vol. 8, 2271-2278 [0002]
- **Sasai, H. ; Arai, T. ; Satow, Y. ; Houk, K. N. ; Shibasaki, M.** *J. Am. Chem. Soc.*, 1995, vol. 117, 6194-8 [0002]
- **Wang, Z. ; Wang, Q. ; Zhang, Y. ; Bao, W.** *Tetrahedron Lett.*, 2005, vol. 46, 4657-4660 [0002]
- **Ooi, T. ; Ohara, D. ; Fukumoto, K. ; Maruoka, K.** *Org. Lett.*, 2005, vol. 7, 3195-3197 [0002]
- **Dere, R. T. ; Pal, R. R. ; Patil, P. S. ; Salunkhe, M. M.** *Tetrahedron Lett.*, 2003, vol. 44, 5351-5353 [0002]
- **Kim, D. Y. ; Huh, S. C. ; Kim, S. M.** *Tetrahedron Lett.*, 2001, vol. 42, 6299-6301 [0002]
- **Wang, J. ; Li, H. ; Zu, L. ; Jiang, W. ; Xie, H. ; Duan, W. ; Wang, W.** *J. Am. Chem. Soc.*, 2006, vol. 128, 12652-12653 [0002]
- **Knudsen, K. R. ; Mitchell, C. E. T. ; Ley, S. V.** *Chem. Commun.*, 2006, 66-68 [0002]
- **Halland, N. ; Aburel, P. S. ; Jorgensen, K. A.** *Angew. Chem., Int. Ed.*, 2003, vol. 42, 661-665 [0002]
- **Yamaguchi, M. ; Shiraishi, T. ; Hirama, M.** *J. Org. Chem.*, 1996, vol. 61, 3520-30 [0002]
- **Yamaguchi, M. ; Shiraishi, T. ; Hirama, M.** *Angew. Chem., Int. Ed.*, 1993, vol. 32, 1176-8 [0002]
- **Evans, D. A. ; Nelson, S. G.** *J. Am. Chem. Soc.*, 1997, vol. 119, 6452-6453 [0029]
- **Lowenthal, R. E. ; Abiko, A. ; Masamune, S.** *Tetrahedron Lett.*, 1990, vol. 31, 6005-8 [0029]
- **Hilgraf, R. ; Pfaltz, A.** *Adv. Synth. Catal.*, 2005, vol. 347, 61-77 [0029]
- **Bhagat, S. ; Sharma, R. ; Sawant, D. M. ; Sharma, L. ; Chakraborti, A. K.** *J. Mol. Catal. A: Chem.*, 2006, vol. 244, 20-24 [0031] [0040]
- **Evans, D. A. ; Borg, G. ; Scheidt, K. A.** *Angew. Chem., Int. Ed.*, 2002, vol. 41, 3188-3191 [0031] [0041]
- *Inorg. Chem.*, 1991, vol. 30, 96-101 [0078]
- *J. Am. Chem. Soc.*, 1997, vol. 119, 6452-6453 [0078]